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Summary 
 
 
The site-specific gene expression in the mouse brain is the most crucial issue for genetic 
studies of brain networks. In our studies, we used different fluorescent proteins (FPs) for 
monitoring brain anatomy, while for the functional analysis, proteins such as Cre 
recombinase and the tetracycline-controlled transactivator (tTA) were investigated. From 
the technical point of view, we attempted both mouse transgenic technology and 
recombinant adeno-associated virus (rAAV) gene delivery in vivo for transferring 
functional proteins into specific cell types of the mouse brain.  
 
First we analyzed the cell-type specificity of a bacterial artificial chromosome (BAC) 
transgene. We selected an enhanced green fluorescent protein (EGFP) recombined BAC 
(from Genesat project) which was supposed to have mitral/tufted cell specific expression 
in the olfactory bulb. By pronuclear injection of the BAC, different founders were 
obtained. Out of 41 potential founders, one was mitral cell specific, and two were specific 
for mitral and tufted cells.    
 
Regarding the limitations of cost and time using the mouse transgenic technology, we 
switched as an alternative approach to the rAAV gene delivery system. For visualizing 
cells that express the virus-delivered proteins, we applied two strategies: one with 
tTA/rtTA and its bi-directional responder Ptetbi to express Cre recombinase together with 
an FP in the specific brain regions. This provided a strong expression level of both Cre 
and FPs in cultured neurons and in neurons in the brain. For the second strategy, we 
applied a slightly modified T2A self-cleaving peptide bridge for the quantitative 
expression of Cre recombinase or tTA/rtTA together with FPs, respectively. By applying 
the T2A peptide approach, two proteins can be almost equally expressed with one rAAV 
construct. This opens a new avenue for gene function analysis in the central nervous 
system.   
 
Next we analyzed whether rAAV can be used for the cell-type-specific expression. We 
selected glia cells, since in the transgenic field, specific promoters are described for 
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proteolipidprotein (PLP) and glial fibrillary acidic protein (GFAP). As second cell 
population we analyzed promoters for local interneurons, the glutamate decarboxylase 67 
(GAD67) and the cholecystokinin (CCK). We investigated a complementation approach 
which splits Cre recombinase into two parts (N-Cre and C-Cre), each driven by a 
different promoter. The Cre recombinase is active when N-Cre and C-Cre are expressed 
in the same cell. With this genetic complementation approach, the infected Cre positive 
cells could be defined as PLP and GFAP or GAD67 and CCK double positive cells, 
respectively. Thus, the cell-type-specific expression is achieved via rAAV delivery, and 
the double positive cells for two different promoters are illustrated with the Cre 
complementation approach. 
 
BAC transgenic technology, rAAV gene in vivo delivery, tTA/rtTA inducible gene 
activation, 2A peptide cleavage approach and the Cre complementation system, all these 
newly developed biological tools can be taken advantage of different aspects for different 
experimental purposes. Moreover, they open a convenient avenue for site-specific and 
cell-type-specific gene expression in manipulating brain circuits. 
Zusammenfassung 
Zusammenfassung 
 
Eine lokal kontrollierte Genexpression bei Mäusen ist einer der wichtigsten 
Forschungsansätze in genetischen Studien zur Gehirnfunktion. In unseren Studien 
analysierten wir verschiedene fluoreszierende Proteine (FPs), die Cre Rekombinase und 
den durch Tetrazyklin regulierten Transaktivator (tTA), die mittels transgener 
Maustechnologie oder rekombinantem Adeno-assoziierten Viren (rAAV) System in das 
Mausgehirn eingebracht wurden. 
 
Zunächst wurde die zelltypische Besonderheit eines Transgens analysiert, das verstärkte 
grün fluoreszierenes Protein (EGFP), das spezifisch im Mausgenom in Mitral-/Tuftzellen 
des Bulbus olfactorius exprimieren sollte. Durch pronukleare Injektion des baterial 
artificial Chromosomes (BAC) wurden verschiedene Gründertiere erzeugt. Von 41 
potentiellen Gründern zeigte einer eine spezifische Expression in Mitralzellen und zwei 
in Mitralzellen und Tuftzellen.  
 
Zwecks einer Reduzierung von Kosten und Zeit, die bei der transgenen Maustechnologie 
anfallen, veränderten wir unsere Vorgehensweise und verwendeten das rAAV 
Gentransfer System. Um Zellen, welche die viral übertragenen Proteine exprimieren, zu 
visualisieren, wurden zwei Strategien angewendet: Zum einen wurden tTA/rtTA mit 
ihrem bi-direktionalen Responder Ptetbi übertragen, so dass Cre Rekombinase zusammen 
mit einem FP in der spezifischen Gehirnregion exprimiert wird. Dadurch wurde ein sehr 
vielversprechendes Expressionslevel von Cre und FPs in kultivierten Neuronen und in 
den injizierten Regionen erreicht. Für die zweite Strategie wurde eine leicht modifizierte 
T2A selbstschneidende Peptidbrücke verwendet, um die quantitative Expression der Cre 
Rekombinase oder auch von tTA/rtTA zusammen mit den FPs zu erreichen. Durch die 
Anwedung des T2A Peptid Ansatzes können zwei Proteine annähernd equimolar durch 
einen rAAV Genetransfer Vektor exprimiert werden. Dies eröffnet neue Möglichkeiten 
der Genfunktionsanalyse im zentralen Nervensystem. 
  
 
Zusammenfassung 
In einem nächsten Schritt untersuchten wir, ob rAAVs für eine zelltypspezifische 
Expression angewendet werden können. Wir wählten Gliazellen, da in der transgenen 
Technologie spezifische Promotoren für das Proteolipidprotein (PLP) und das saure 
Gliafaserprotein (GFAP) beschrieben sind. Als zweite Zellpopulation analysierten wir die 
Promotoren für lokale Interneuronen,  Glutamat Decarboxylase 67 (GAD67) und 
Cholecystokinin (CCK).  Wir untersuchten einen Komplementierungsansatz, welcher die 
Cre Rekombinase in zwei Teile (N-Cre and C-Cre) auftrennt, wobei dieser Vorgang unter 
der Kontrolle von zwei verschiedenen Promotoren abläuft. Durch die Verwendung dieses 
Ansatzes wurde gezeigt, dass die Cre Rekombinase nur exprimiert wird, wenn beide 
Promotoren zur selben Zeit in der selben Zelle aktiv sind.  Mit dem genetischen 
Komplementierungsansatz können die infizierten Cre positiven Zellen als PLP und GFAP 
oder GAD67 und CCK doppelt positive Zellen definiert werden. So wird die Zelltyp 
spezifische Expression durch rAAV Übertragung erreicht und die doppelt positiven 
Zellen für zwei verschiedene Promotoren durch den Cre Komplementierungsansatz 
dargestellt. 
 
Mit all diesen neu entwickelten biologischen Werkzeugen, transgene BAC Technologie, 
in vivo rAAV Genübertragung,  tTA/rtTA induzierbare Genaktivierung, der 2A Peptid 
Ansatz und das Cre Komplementierungssystem, kann ein Vorteil für verschiedene 
Aspekte und experimentelle Zwecke erzielt werden. Darüber hinaus eröffnen sie eine 
gute Möglichkeit der ortsspezifischen und zelltypspezifischen Genexpression, indem sie 
die Gehirnschaltkreise manipulieren.  
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1. Introduction 
 
The amazing complexity of mammalian brain represents the composition of billions 
of neurons, including thousands of cell types, connected into circuits by trillions of 
synapes. The essential goal of neuroscience today is no longer the investigation of 
single neurons, but comprehending the principles of organizing these complex circuits 
and thereby to explain how they process information and guide the behavior.  
 
The large number of cells existing in our brain consist actually of a large variety of 
heterogeneous neuron/cell populations. At a microscopic level,  in the olfactory 
system for example, different neuronal populations respond preferentially by the 
olfactory sensory inputs (Mombaerts et al., 1996; Wachowiak et al., 2004; Shipley 
and Ennis, 1996). At a larger scale, cortex and hippocampus appear to be organized in 
spatially segregated areas associated with different functions (Andersen et al., 2007). 
To distinguish the function of different brain regions and diverse neuron/cell types, 
the most commonly used method for their characterizations is to look for genes 
expressed specifically in different locations or types of neurons/cells, for instance 
glutamate decarboxylase 67 (GAD67) for local interneurons and glial fibrillary acidic 
protein (GFAP) for glial cell expression. For further in vivo studies, transgenic mice 
were generated, in which the promoters for these site-specific or cell-type-specific 
genes drive the expression of either a fluorescent protein for visualization of cells that 
express the functional protein, such as Cre recombinase. In our study, we attempted 
from different aspects with several newly developed biological tools to achieve site-
specific and cell-type-specific gene expression in the mouse brain, and therefore, offer 
new options for experimental design of genetically based studies in neuroscience.  
 
1.1 Bacterial artificial chromosome (BAC) transgenic mouse model 
 
Transgenic technology via microinjection of DNA into the pronuclei of fertilized 
oocytes is a commonly used method for gene transfer into the mouse genome (Gordon 
et al., 1980; Gordon and Ruddle, 1981). Not only small size plasmid DNA (Nagga et 
al., 2002; Pinkert and Polites, 1994), but also bigger size DNA fragment, such as 
bacterial artificial chromosome (BAC, Nielsen et al., 1997, Yang et al., 1997), can be 
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used for the generation of transgenic mice. Mice transgenic technology combined 
with bacterial artificial chromosome (BAC) recombineering (recombination-mediated 
genetic engineering, Copland et al., 2001) is a very powerful tool for the highly 
efficient tissue-specific expression in the mouse brain, since a single BAC contains 
the intact gene of interest and all its regulatory components for gene expression. The 
native genomic surrounding sequence can later protect the transgene from being 
influenced by other local genes that may come in next proximity during random 
genomic insertion. At the beginning of our study, we chose an EGFP recombined 
BAC which appears to limit its gene (gap junction α9) expression only in mitral cells 
in the mouse olfactory bulb. 
 
1.2 Mitral and tufted cells 
 
Mitral/tufted cells are the projection neurons in the mouse olfactory system, which 
receive input information via their dendrites from the olfactory sensory neurons 
(OSN) and process the information through their axons to the olfactory cortex (Buck 
and Axel, 1991; Zhang and Firestein, 2002; Zhao et al., 1998; Satou, 1990; Shipley 
and Ennis, 1996). Cell bodies of mitral cells are lined in the thin mitral cell layer 
(MCL), whereas those of tufted cells are distributed in the external plexiform layer 
(EPL) and glomerular layer (GL) (Figure 1.1a). In addition, the two types of neurons 
differ in the size of cell body and the terminal tuft of primary dendrite within the 
glomeruli, projection pattern of their secondary dendrites, laminar distribution of 
axon-collaterals within the OB, and the pattern of axonal projection to the olfactory 
cortex (Figure 1.1b) (Haberly and Price, 1977; Mori et al., 1983; Orona et al., 1984; 
Pinching and Powell, 1971; Schoenfeld and Macrides, 1984; Schoenfeld et al., 1985; 
Scott et al., 1980; Skeen and Hall, 1977). 
 
Since mitral and tufted cells are the projection neurons of the olfactory bulb, and 
transmit the olfactory information from the periphery to the central nervous system 
(Shepherd et al., 2004), genetically marking mitral/tufted cells and manipulating their 
properties is crucial for the further understanding of olfactory circuits. We attempted 
to apply the BAC transgenic model to specifically outline this cell population in 
mouse olfactory bulb. 
 
Introduction 
 3 
       
Figure 1.1 Organization of mouse main olfactory bulb. (a) Coronal image of mouse main olfactory 
bulb. Blue: Glomerular layer; Red: External Plexiform and Mitral cell layer; Green: Internal Plexiform 
and Granule cell layer. Scale: ventral to dorsal, is approximately 2mm. (From 
http://en.wikipedia.org/wiki/Olfactory_bulb) (b) Scheme of illustrating the morphological difference 
between mitral cells and middle tufted cells. Mitral cells have a relatively large cell body in the mitral 
cell layer (MCL). They extend long secondary dendrites in the deeper half of the external plexiform 
layer (EPL) and form synapses with the dendrites of granule cells (type II). They project their axons to 
the entire part of the olfactory cortex. Middle tufted cells have a relatively small cell body and are 
scattered in the EPL. They extend relatively short secondary dendrites to the superficial half of the EPL 
and form with granule cells (type III). Tufted cells project their axons only to the anteromedial part of 
the olfactory cortex. ONL: olfactory nerve layer; GL: glomerular layer; IPL: internal plexiform layer; 
GCL: granule cell layer. (From Nagayama et al., 2004). 
 
1.3 Gap junction α9 (Gjα9) gene 
 
To genetically marking mitral/tufted cells, Gap junction α9 (Gjα9) gene was chosen 
as the candidate. Gap junctions are clusters of intercellular channels sitting on 
neighboring cells that permit passage of small molecules of up to 1,000 kDa, such as 
ions, second messengers and small metabolites. These intercellular membrane 
channels are also called connexons. Each connexon is composed of subunit proteins, 
called connexins (Cxs).  These gap junctions are presented in almost all cell types of 
vertebrate organisms, and in the nervous system (Beyer et al., 1990; Willecke et al., 
1991; Bruzzone and Ressot, 1997). 
 
The Gjα9 is also named as Connexin 36 (Cx36), which belongs to the connexin 
family. It appears to be preferentially expressed in the adult and developing central 
nervous system (CNS) in neurons known to be electrically coupled (Condorelli et al., 
1998), such as the inner and outer plexiform cell layers of the retina, the olfactory 
bulb, pineal gland, inferior olive, superficial layers of the neocortex, the purkinje cell 
layer of the cerebellum, pyramidal cells of the CA3/CA4 region of adult 
hippocampus, and motor neurons in the spinal cord (O'Brien et al., 1996; Söhl et al., 
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1998; Condorelli et al., 1998; Al-Ubaidi et al., 2000; Guldenagel et al., 2000; Parenti 
et al., 2000; Rash et al., 2000; Rozental et al., 2000; Teubner et al., 2000; Feigenspan 
et al., 2001).  
 
Due to the abundant expression in the mitral cells shown in in situ hybridization 
analysis of Gjα9 in adult rat brain (Figure 1.2, Condorelli et al., 1998) and the 
indication from the Gjα9 gene knockout mice that coupled AMPA response between 
mitral cell pairs were absent (Christie et al., 2005), we chose the BAC clones which 
contains the complete Gjα9 gene sequence and the first exon of the gene was 
substituted with EGFP sequence for generating mitral cell specific expression mouse 
line via BAC transgenic mouse technology. 
                     
Figure 1.2 In situ hybridization analysis of Gjα9 transcripts in rat brain.  Tissue section was 
hybridized by 35S labeled probes. Darkfield microphotographs of representative autoradiogram of 
sagittal whole brain section hybridized with an antisense probe. Arrows indicate the expression in 
hippocampus. Cb: cerebellum; Cx: cerebral cortex; H: hippocampus; Hy: hypotalamus; IC: inferior 
colliculus; Mo: medulla oblongata; OB: olfactory bulb; Pn: basilar pontine nuclei; ST: striatum. (From 
Condorelli et al., 1998). 
 
1.4 Recombinant adeno-assoiated virus (rAAv) gene delivery 
 
Regarding limitations of the mouse transgenic technology, and to investigate other 
alternative approaches, we switched to the rAAV gene delivery system, which is more 
flexible and timesaving in the achievement of the site-specific and cell-type-specific 
gene expression in the mouse brain. 
 
1.4.1 Recombinant adeno-associated virus (rAAV) as gene delivery approach 
 
Since the early 1980s, the successful cloning of adeno-associated virus (AAV) 
established the capability to express foreign genes within the recombinant AAV 
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(rAAV) vector in mammalian cells (Samulski et al., 1982; Laughlin et al., 1983), 
rAAV has become an attractive and promising delivery vector for gene therapy 
approach. The rAAVs are nonpathogenic, that all viral genes were removed, and the 
replication is dependent on co-infection with a helper plasmid (Muzyczka and Berns, 
2001). The rAAV production and purification methods have also already very well 
established (Kaludov et al., 2002; Zolotukhin et al., 2002; Smith et al., 2003; Blouin 
et al., 2004; Davidoff et al., 2004). The fact that rAAV can target neurons in the 
nervous system, has made this vector a valuable system for the delivery of genes to 
the brain for functional studies of the nervous system. Therefore, the combination of 
cell-type selective promoters and local delivery of rAAV could provide a great chance 
for the brain tissue-specific labeling and the further manipulation of the brain circuits. 
 
1.4.2 Genomic structure of rAAV 
 
Adeno-associated virus (AAV) is a small non-enveloped virus that belongs to the 
parvovirus family (Blacklow, 1988; Berns et al., 1996). It was initially discovered as 
a contaminant in adenovirus preparations (Atchison et al., 1966; Hoggan et al., 1966).  
The AAV is a single-stranded DNA virus and is packaged as a plus or a minus strand. 
The viral genome is approximately 4.7 kilobase pairs (kb) in length, and is composed 
of two major open-reading frames encoding Rep (replication) and Cap (capsid) 
proteins. Four Rep proteins (Rep 78, Rep 68, Rep 52, and Rep 48) are generated from 
the 5’ open-reading frame through the use of two different promoters and alternative 
splicing (Mendelson et al., 1986). The 3’ open reading frame of wild-type AAV 
generates three capsid proteins (VP1, VP2, and VP3) through alternative splicing and 
alternative start codon usage (Trempe et al., 1988) (Figure 1.3a). The virion particle 
has icosahedral (20-faced) symmetry with a diameter of 26 nm and a molecular 
weight of 5.5 - 6.2 million Daltons (MDa) (Buller et al., 1978; Muzyczka, 1992; 
Berns, 1996; Linden et al., 2000).  
 
In rAAV, the Rep and Cap genes are removed from the vector and replaced by a 
target transgene cassette or genes of interest (Figure 1.3b, promoter, cDNA of genes 
of interest and polyadenylation site).  
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Figure 1.3 Structure of wild-type and vector AAV genomes. (a) Map of the wild-type AAV 
genome, including Rep (solid) and Cap (open) reading frames, promoters (p5, p19, and p40), 
polyadenylation site (pA), and inverted terminal repeats (ITR). The viral transcripts encoding the 
different Rep and Cap (VP1-3) proteins are shown below the genome. The smaller Rep proteins, VP2 
and VP3, are translated from internal initiation sites. (b) Map of a typical AAV vector, showing 
replacement of the viral Rep and Cap genes with a transgene cassette (promoter, transgene cDNA, and 
polyadenylation site). (c) Secondary structure of the AAV ITR, with the locations of the Rep binding 
site (RBS) and terminal resolution site (TRS) indicated. (From Russell and Kay, 1999) 
 
The two viral genes are flanked by the inverted terminal repeats (ITRs, 145 bp in 
length for AAV2, Lusby et al., 1980). These ITRs are self-complementary and GC-
rich sequence (Figure 1.3 c). The stable T-shaped hairpin plays a very important role 
in the AAV genome and is the only necessary viral component in recombinant vector 
genomes. Included in the ITR are two motifs, a terminal resolution site (TRS) and a 
Rep binding site (RBS), which are necessary for replication and encapsidation of the 
viral genome.  
 
1.4.3 Serotypes 
 
To date, more than 110 primate’s AAV capsid sequences have been identified (Gao et 
al., 2005). Each of those that have unique serological profiles was named as a 
particular AAV serotype. And 12 primate’s serotypes (AAV1 - 12) have been 
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described (Rutledge et al., 1998; Xiao et al., 1999; Samulski et al., 1983; Muramatsu 
et al., 1996; Chiorini et al., 1997; Chiorini et al., 1999; Gao et al., 2002; Gao et al., 
2004; Mori et al., 2004; Schmidt et al., 2008). Because different AAV serotypes enter 
cells via distinct cell surface receptors (Summerford and Samulski, 1998; Qing et al., 
1999; Summerford et al., 1999; Walters et al., 2001; Di Pasquale et al., 2003), it was 
hypothesized that different serotypes would target diverse tissue types. Numerous 
studies have evaluated and compared different serotypes regarding their transduction 
efficiency in tissues in vivo, such as different cell types and brain regions. 
 
So far rAAV1, rAAV2, rAAV4, rAAV5, rAAV6, rAAV7 and rAAV8 have been 
tested in the nervous system (Alisky et al., 2000; Davidson et al., 2000; Yang et al., 
2002; Passini et al., 2003; Vite et al., 2003; Burger et al., 2004; Taymans et al., 
2007). The most commonly used vector has been based on AAV2. It has been 
successfully used to transduce adult mammalian brain, where mainly neurons are 
targeted (Davidson et al., 2000). However, rAAV1 and rAAV5 have demonstrated a 
higher distribution and number of neurons transduced than rAAV2 in the CNS, such 
as in striatum, hippocampus, globus pallidus, substantia nigra, spinal cord, and 
cerebellum (Alisky et al., 2000; Davidson et al., 2000; Wang et al., 2002; Burger et 
al., 2004; Paterna et al., 2004). Recent studies have shown greater infection efficiency 
with rAAV7 and rAAV8 than with rAAV2 in striatum, hippocampus, globus pallidus 
and substantia nigra in mouse brain (Taymans et al., 2007). In our study, to achieve 
high virus infection both in vitro and in vivo, we used a cross-packaging of rAAV1 
and rAAV2. 
 
1.4.4 Principle of the rAAV gene delivery system 
 
Since rAAV is a replication defective virus, the production of the recombinant viral 
vector needs help from either a helper virus, such as adenovirus, or of some genes 
from the helper virus. The original protocol was using adenovirus (Hermonat and  
Muzyczka, 1984; Zhou and Muzyczka, 1998; Flotte and Carter, 1995) or herpes 
simplex virus (Conway et al., 1997)  as helper virus. However, the adeno or herpes as 
helper virus in the rAAV production should be avoided for in vivo applications. To 
avoid contamination, the required helper genes E4, E2A, and VA from adenovirus 
were used to construct helper plasmids. These helper plasmids were termed pDG 
Introduction 
 8 
plasmids (Figure 1.4). Not only E4, E2A, and VA from adenovirus, but also rep 
genes from AAV were inserted into these plasmids. The rep gene is from AAV2, 
while the cap gene originates from serotypes 1 - 6, thus 6 helper plasmids were cloned 
for 6 different serotypes (pDG1 – 6, Grimm et al., 1998; 2003).  
 
                            
Figure 1.4 Map of pDG plasmid. Plasmid pDG carries all genes essential for packaging of AAV-2 
vectors, i.e., AAV-2 rep and cap genes and VA, E2A, and E4 genes of adenovirus 5. Five novel helper 
constructs were derived from pDG by exchanging the AAV-2 cap gene with cap of AAV serotype 1, 3, 
4, 5, or 6. (From Grimm et al., 2003). 
 
 
1.4.5 The rAAV production 
 
The cross-packaging of rAAV vector plasmid and different pDG helper plasmids was 
about 10 times more efficient than the traditional adenovirus-help method (Grimm et 
al., 1998; 2003). Figure 1.5 shows the general scheme of rAAV production. 
                    
Figure 1.5 General Scheme of rAAV2 vector production. The rAAV vectors have been constructed 
by removal of endogenous viral genes, and insertion of an expression cassette(s) between flanking 
ITRs. The rAAVs are generally encapsidated by transfection of a plasmid containing the rAAV vector 
into cells with provision of AAV rep and cap (as either plasmids or by using cells expressing them) and 
'helper' virus functions such as Adenovirus E1, E2, E4, and VA RNAs (either as a plasmid or by viral 
infection). The resulting vector is then purified using density gradient centrifugation (CsCl2 or 
Iodixanol) and/or column purification. (From Sun et al., 2003). 
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1.4.6 Cellular entry and trafficking of rAAV 
 
Understanding the rAAV cellular entry and trafficking is very important for 
improving the efficiency of rAAV-mediated gene delivery. The entry and trafficking 
can be divided into several steps (Figure 1.6). First, the viral particles attach to the 
cell surface by binding to the receptor. The most significant factor effecting viral 
binding is the abundance of AAV receptors. This stage can be most significantly 
influenced by the choice of rAAV serotype or type of capsid variant used to generate 
the recombinant virus. Second stage is receptor-mediated endocytosis of the virus. 
This step may be influenced by the AAV co-receptors on the surface of the target 
cells, which can trigger the endocytosis. Next stage involves rAAV movement to the 
nucleus, including vesicular trafficking, endosomal escape and nuclear transport. The 
final post nuclear step for rAAV trafficking is viral uncaging and genome conversion 
of the single-stranded rAAV genome to double-stranded DNA, which is capable of 
expressing transgenes (Douar et al., 2001; Yan et al., 2004; Xiao et al., 2002; Hansen 
et al., 2000). 
 
 
 
Figure 1.6 Cell entry and trafficking of recombinant adeno-associated virus (rAAV). Stages and 
events during AAV cell transduction. Transduction of target cells by AAV is initiated by viral binding 
of AAV to the cell-surface receptor and co-receptors, followed by internalization (endocytosis), 
trafficking to the nucleus, nuclear entry and uncoating, and nuclear gene expression. (From Schultz and 
Chamberlain, 2008). 
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1.5 Tetracycline-controlled transactivator (tTA) inducible gene expression 
 
By applying rAAV gene delivery approach, the functional proteins, such as Cre 
recombinase, can be flexibly expressed at the desired brain regions. However, the in 
vivo visualization of delivered genes is still an unsolved issue. To fulfill this, a 
delivery method of two different proteins is required. At the beginning of the rAAV 
work, we took tetracycline-controlled transactivator (tTA) or reverse tTA (rtTA) 
inducible gene expression system which has been used to regulate gene expression in 
a number of species. It was first described by Gossen and Bujard (Gossen and Bujard, 
1992) and is the best characterized and well studied regulated promoter system. The 
system is based on the E.coli tetracycline-resistance operon, a regulatory unit that 
detects minute concentration of tetracycline and mounts an appropriate resistance 
response. Since the elements are derived from a prokaryotic organism, there is no 
endogenous expression in mammalian cells (Gossen et al., 1993).  
 
1.5.1 Principles of the Tet-controlled gene expression 
 
1.5.1.1 Inducible Tet-system in prokaryotes 
 
The tTA-system is based on regulatory elements of the Tn10- tetracycline-resistance 
operon from E.coli (Gossen and Bujard, 1992). In Gram-negative bacteria, 
tetracycline (Tet) can kill bacteria by blocking protein synthesis (Epe and Woolley, 
1984). A gene called TetA mediates resistance to Tet (Yamaguchi et al., 1990). In the 
absence of Tet, TetA is not expressed since it is blocked by the tetracycline repressor 
(TetR), which binds in the TetR and TetA promoter regions to the operators, tetO1 
and tetO2, respectively. This results in a transcriptional blockade of TetR and TetA, 
thereby down-regulating expression of TetR and TetA. In the presence of Tet, Tet 
binds to TetR, thereby reducing the affinity of TetR to the tetOs, which results in the 
loss of the transcriptional blockade.   
 
1.5.1.2 Tet-controlled gene expression in Eukaryotes 
 
The Tet regulation system from prokaryotes has been adapted for experimental gene 
regulation in eukaryotes by fusing TetR to the VP16 transcriptional activating domain 
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from herpes simplex virus VP16, thereby creating a synthetic tetracycline-regulated 
transcriptional activator protein (tTA) that can be used to regulate a gene that is under 
the control of a tetracycline-responsive promoter, so called Tet-inducible system 
(Gossen and Bujard, 1992). This system consists of two components, the Tet- 
controlled transactivator protein (tTA), and the Tet-regulated element (TRE). The tTA 
is a fusion protein of the TetR and the C-terminal VP16 protein. The TRE region 
consists of seven copies of tetOs and a minimal cytomegalovirus (CMV) promoter 
that contains the transcription start site with a TATA box (Ptet). The TetR-VP16 
fusion protein binds to tetO sequences located in front of the minimal promoter via 
the TetR domain, while the C-terminal VP16 domain participates in the recruitment of 
the RNA polymerase II (Pol II) transcriptional initiation complex. In the absence of 
tetracycline, tTA binds to the Ptet and drives the expression of the downstream gene. 
The addition of tetracycline to the medium prevents tTA from binding the tetO 
sequence and the promoter is inactive (Figure 1.7). 
 
           
Figure 1.7 Principle of the Tet-Off-system. (a) When the constitutively expressed tTA binds to tetO7 
(Ptet), tTA initiates transcription. (b) In the presence of Tet, tTA is unable to bind to Ptet and Ptet -
controlled gene transcription is turned-off (Tet-Off). (From Sprengel and Hasan, 2007). 
 
1.5.1.3 The reverse tTA (rtTA) system 
 
A variation of this system uses a ‘reverse’ tetracycline transactivator (rtTA). This was 
achieved by exchanging the TetR of tTA by a TetR mutant with four point mutations 
(E71K, D95N, L101S and G102D) to generate the reverse tTA (rtTA). The rtTA only 
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binds tetO in the presence of tetracycline. In this case, a gene under Ptet-control is 
expressed in the presence of tetracycline, but not in its absence (Hecht et al. 1993; 
Gossen et al. 1995).  
 
1.5.1.4 Improvement of the tTA system 
 
Since the original tTA system was derived from prokaryotic system, the application of 
this system on mouse transgenics is relatively limited. It is difficult to generate 
transgenic mice expressing the tTA to direct efficiently a gene of interest in a region 
specific manner in brain (Kim, 2001; Jerecic et al., 1999). Replacement of the VP16 
activation domain by three copies of a 12 amino acid minimal activation F-domain, 
improved its tolerance in mammalian cells (Baron et al., 1997; Kim, 2001). 
Additionally, a nuclear localization signal sequence located at the N-terminus of tTA 
and improved the binding efficiency of tTA on the Ptet responder in the nucleus 
(Figure 1.8). 
 
 
Figure 1.8 Schematics of tTA and improved tTA composites. The TetR-core region with 10 α-
helices (1–10) contains sites for tetO-binding, Tet-binding and homodimerization. VP16 or minimal F-
domains make up the transactivation domains. The position of the nuclear localization domain (n) is 
indicated. (From Sprengel and Hasan, 2007). 
 
1.5.2 The Tet-inducible gene expression via rAAV delivery  
 
The transgenic approaches (Sprengel and Hasan, 2007) for site- and cell-type specific 
expression is very time consuming and in many cases unsuccessful. As already 
mentioned above, rAAV mediated gene delivery is a fast and efficient method for the 
gene expression both in vitro and in vivo. It is also a very attractive method to deliver 
Tet-regulated genes into experimental animals. The two components (tTA activator 
and tetO responder) of the Tet-inducible system can be inserted into two separate 
rAAV vectors (McGee Sanftner et al., 2001; Zhu et al., 2007). The tTA activator 
expression can be driven by a cell-type-specific promoter to achieve cell type 
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specificity. In our study, tTA activator virus was driven by the Synapsin promoter to 
achieve neuron specificity and local injection of rAAV could mediate desired site-
specific expression in the mouse brain.  
 
1.5.3 The tTA/rtTA dependent Ptet-bi promoter 
 
As described above, the TRE region on the tTA/rtTA responder vector has seven 
copies of tetOs and a minimal cytomegalovirus (CMV) promoter that contains the 
transcription start site with a TATA box. This vector is named ‘Ptet’ responder vector 
(Figure 1.9). Additional insertion of another CMV minimal promoter containing 
TATA box on the opposite side of tetO7 produced a bi-directional Tet promoter (Ptet-
bi), which enables the expression of two genes with one responder vector. This offers 
us the possibility for expressing two genes (a functional protein and a fluorescent 
protein) within one construct and could be at the same time controlled by the 
tTA/rtTA inducible system. 
               
Figure 1.9 Scheme of Ptet and Ptet-bi promoters. The different promoter elements of the two 
tTA/rtTA-controlled promoters are depicted. Nucleotide positions relative to the transcriptional start 
sites (position +1) are indicated. (From Sprengel and Hasan, 2007) 
 
To apply the tTA/rtTA inducible system together with the rAAV delivery approach, 
we tested the feasibility of this combination under both in vitro and in vivo conditions, 
and demonstrated the efficient dual gene expression in the brain. The rtTA Tet-on 
system also showed very robust gene activation upon the induction of Doxycycline, a 
Tetracycline derivative. Furthermore, with the strong gene activation, the anatomic 
brain circuits of infected brain regions were clearly visualized by fluorescent proteins, 
indicating the contribution of local individual neurons to the entire brain circuits. 
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1.6 The 2A peptide-mediated self-processing  
 
Although the tTA/rtTA inducible system combined with rAAV gene delivery 
approach shows a very efficient gene expression level, the Ptet based bi-cistronic viral 
vectors have to be used with great care. The strengths of the left and right promoters 
were never quantified and the translation efficiencies and mRNA stabilities of two 
gene products can be very different. Conventionally, rAAV delivery of multiple genes 
within a single transcriptional unit was performed mainly using internal ribosomal 
entry sites (IRES) from picornavirus or by using Ptet based bi-cistronic viral vectors 
as metioned above (Zhu et al., 2007). The IRES is a nucleotide sequence that allows 
for translation initiation at any position of an mRNA sequence. However, in many 
examples translational initiation at IRES elements is too weak for efficient gene 
expression, and large sequence (~500 nucleotides) also results the limitation 
(Hennecke, et al., 2001). 
 
An alternative and more promising approach involves the use of self-processing viral 
peptide bridges. So-called 2A or 2A-like peptide sequences separate different protein 
coding sequences in a single ORF transcription unit of Picornaviridae (Ryan et al., 
1991). The 2A peptide sequences from different members of the picornavirus family 
share a highly conserved motif of only 18 amino acids, mediating the cleavage 
between the C-terminal glycine and the N-terminal proline of the downstream 2B 
sequence (Ryan et al., 1991). Initially, the 2A peptide was supposed to have an auto-
proteolytic event (Ryan et al., 1991), therefore, it was termed as “self-cleaving 
peptide”. Ultimately, a ribosomal-skip mechanism was proposed, and 2A and 2A-like 
sequences are referred to as cis-acting hydrolase elements (CHYSEL), rather than 
self-cleaving peptides (de Felipe et al., 2006). However, 2A or 2A-like peptide 
sequences do result a cellular expression of multiple, discrete proteins (in essentially 
equimolar quantities), derived from a single ORF (de Felipe et al., 2006).  
                                        
Figure 1.10 Amino acid sequence of 2A peptide from Thosea asigna virus. The arrow indicates the 
cleavage site.  
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The 2A peptide-mediated cleavage has previously been shown to result in faithful co-
expression of heterologous proteins in different cell lines (de Felipe et al., 2006) and 
in neurons (Furler et al., 2001). Surprisingly, the potential of this system has not been 
exploited in cellular and systems neuroscience. In particular, it has not been addressed 
whether 2A peptide-mediated co-expression of heterologous proteins is quantitative in 
neurons and expression levels of fluorescent reporters would be high enough for in 
vivo imaging applications. Another important point is to ensure that 2A peptide 
transcripts have no detrimental impact on neuronal viability and function.  
To address these questions, we analyzed the efficiency of co-expression of various 
proteins in neurons in vitro and in vivo, using a peptide bridge from Thosea asigna 
virus (Donnelly et al., 2001). We demonstrate that this system has clear advantages 
because it achieves efficient and reliable functional co-expression of multiple proteins 
in neurons in vivo. We also show that viral co-expression of Cre recombinase (Sauer, 
1993) or a tetracycline-controlled transactivator (tTA, Kistner et al., 1996) with 
fluorescent proteins (FPs) is compatible with in vitro and in vivo gene expression and 
imaging approaches and can be combined with inducible genetic mouse models to 
enable targeted manipulation of faithfully labeled neuronal subgroups.  
1.7 Cre recombinase and Cre complementation system 
 
After achieve the site-specific expression in the mouse brain by applying two 
different strategies, we next analyzed whether rAAV can be used for the cell-type 
specific expression of Cre recombinase in vivo via a Cre complementation system.  
 
The bacteriophage P1 possesses a site-specific recombination system, the Cre/LoxP 
system. Expression of Cre recombinase results in recombination between pairs of 34-
bp LoxP elements in direct orientation (Abremski and Hoess, 1984). Cre mediated 
deletion of floxed alleles is a powerful tool to study gene function in conditional 
knockout mouse models. The locally restricted and time induced expression of active 
Cre permits a precise analysis of gene function in subsets of cells. Particularly in 
neuroscience, Cre-mediated mutagenesis is full of importance, since most of the CNS 
specific genes are expressed in many different brain regions and in global gene 
knockout can thus lead to a complex phenotype. 
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Although the Cre/LoxP-system has been widely used to analyze the cell-type-specific 
function of a gene by conditional inactivation or conditional ectopic expression 
(Lewandoski, 2001; Bockamp et al., 2008), in many cases a single marker gene or a 
single promoter activity is not sufficient to identify a certain cell type unequivocally 
(Luo et al., 2008). For instance, local interneurons in the forebrain release the 
transmitter γ-aminobutyric acid (GABA) (Monyer and Markram, 2004; Markram et 
al., 2004; Maccaferri and Lacaille, 2003) and therefore, express the enzyme glutamate 
decarboxylase (GAD). However, among all interneurons there are many 
subpopulations regarding expression of various combinations of different proteins or 
neuropeptides, such as calcium-buffering proteins (parvalbumin, calbindin) and 
cholecystokinin (CCK) (Pawelzik et al., 2002; Somogyi et al., 1984; Markram et al., 
2004). These markers are not only expressed in interneurons, but also some other 
neuron types. Therefore, genetically targeting of these marker-positive interneurons 
by driving Cre recombinase from a single promoter will almost certainly hit several 
distinct neuron types. 
 
To overcome this limitation, a novel Cre complementation system was developed to 
introduce a second promoter controlling the range of recombination based on the 
complementation of Cre-protein fragments. This was achieved by constructing fusion 
proteins of a constitutive protein-protein interaction domain with either an N- or C-
terminal Cre fragment (designated N-Cre and C-Cre, respectively, Jullien et al., 2003; 
2007). Each of these ‘split-Cre’ proteins is driven by a distinct promoter, and does not 
catalyze DNA-recombination alone. Expressed together in one cell they readily 
assemble into a functional enzyme in vivo (Figure 1.11). 
  
Figure 1.11 Principle of Cre complementation system. The expression of N-Cre and C-Cre are 
placed under the control of two different promoters (promoter 1 and 2, respectively). Only if both 
promoters are active, functional complementation takes place and LoxP (red triangles) – flanked 
sequences are recombined, thereby activating/inactivating reporter genes. 
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We combined this complementation system with the rAAV gene delivery approach, 
the infected Cre positive cells could be defined as double-promoter (promoter1 and 
promoter2) positive cells. Thus, the cell-type-specific expression can be achieved 
with the rAAV system and double positive cells for two different promoters are 
illustrated with the Cre complementation system. 
 
In summary, with our study of site-specific and cell-type-specific gene expressions of 
visualized functional proteins, we could combine some new tools for different 
experimental goals which permits a new level of gene manipulation of the neuronal 
circuits in the brain of animals. 
Results 
 18 
2. Results 
 
2.1 Generation of transgenic mice expressing EGFP in mitral cell layer in mouse 
olfactory bulb 
 
We first applied the BAC transgenic technology in the hope to achieve the specific 
expression of enhanced green fluorescent protein (EGFP) in mitral/tufted cells in 
mouse olfactory bulb. Bacterial artificial chromosome (BAC) modification was 
performed by the GENSAT project at the  Rockefeller University. Using BAC 
recombinerring technique, a BAC containing mouse gap-junction-α9 gene (Gjα9) 
was modified by homologous recombination (Gong et al., 2002), yielding the 
replacement of the first exon of Gjα9 by EGFP sequence. NotI linearized BAC DNA 
was then purified by sucrose gradient and injected into pronuclei of fertilized mouse 
oocytes at the Interfakultäre Biomedizinische Forschungseinrichtung (IBF) 
Heidelberg to generate several transgenic mouse lines. 
 
By tail biopsy and genomic PCR, the existence of EGFP in founder animals was 
assessed. Twelve out of 41 potential founders were identified. To further characterize 
the expression pattern of these founders, they were bred with wild-type C57Bl/6 mice 
to obtain F1 generation. For unknown reasons some of those founders lacked 
transgene transmission or the ability to reproduce, only 8 provided F1 offspring. The 
F1 mice were analyzed by anti-GFP immunostaining of brain sections at postnatal day 
42 (P42). All mice from F1 generation showed EGFP expression in olfactory bulb and 
other brain regions with different expression intensities and cell-type specificities. 
Three founder lines were selected, which showed very strong expression in the 
olfactory bulb. 
 
The F1 offspring from founder 27 showed strong expression restricted to mitral cells 
in the olfactory bulb. Most mitral cells are labeled and as well as their axon 
projections. The lateral olfactory tract, which is composed of axon projections from 
mitral cells, could be detected in piriform cortex (Figure 2.1 a). The F1 mice from 
founder 30 had less labeled cells in the mitral cell layer, but showed expression in 
some other brain regions, such as hippocampus and cortex (Figure 2.1 b). The F1 
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mice from founder 32 showed strong labeling in both mitral and tufted cells in the 
olfactory bulb. The lateral olfactory tract was as well strongly immunolabeled 
(Figure 2.1 c). 
 
Figure 2.1 Founder analysis of Gjα9 BAC transgene by DAB staining. (a) Founder line F27, only 
mitral cells were labeled in the olfactory bulb, the lateral olfactory tract was indicated by black arrow. 
(b) Founder line F30 shows the EGFP expression in mitral cells in the olfactory bulb, in hippocampus 
and somatosensory cortex (from left to right, respectively). (c) Founder line F32, both mitral (indicated 
by red arrow) and tufted (indicated by green arrow) cells are detected in the olfactory bulb, and lateral 
olfactory tract is indicated by black arrow. All sections are coronal sections, scale bar: 125 µm.   
          
Figure 2.2 Native fluorescence in olfactory bulb from in-bred offspring of founder line F27. 
Mitral cells were clearly detected by EGFP fluorescence, in both cell bodies and dendrites. Scale bar: 
50 µm. 
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Although the native fluorescence in the olfactory bulb from founder line F27 can be 
detected, the intensity of EGFP was not very high. Therefore, in-bred offspring was 
used to obtain higher fluorescent expression. Olfactory bulb sections from in-bred 
offspring were directly placed under the fluorescent microscope after perfusion and 
fixation. And as expected, EGFP fluorescence could be detected clearly in the cell 
bodies of mitral cells as well as in their dendrites (Figure 2.2).  This finding would 
offer the possibility for mouse olfactory bulb in vivo imaging with two-photon 
microscopy.  
 
2.2 Multiple gene expression via recombinant adeno-associated virus (rAAV)  
      gene delivery 
      
Bacterial artificial chromosome (BAC) modification and mouse transgenic 
technology as applied above is often used for tissue-specific labeling. However, this 
method is expensive and is time-consuming. Therefore, we changed to a virus 
mediated gene transfer as a short cut method for tissue-specific gene transduction and 
gene manipulation.  
 
2.2.1 Tetracycline-controlled transactivator (tTA) inducible gene expression  
 
Considering the visualization of cells with virus delivered proteins by fluorescent 
proteins, we applied an inducible gene expression system, the tetracycline-controlled 
transactivator (tTA) system, combined with rAAV gene delivery approach. With this 
system, two heterologous proteins can be expressed with one Ptet-bi vector. At the 
same time, the expression of the Ptet-bi controlled genes can be regulated by the tTA 
or rtTA.  
 
2.2.1.1 Tetracycline-controlled transactivator (tTA) induced iCre and Venus 
            expression in hippocampal neuron culture 
 
Tetracycline-controlled transactivator (tTA) induced responder gene expression was 
introduced into the rAAV system as described before (Zhu et al., 2007). Both 
activator construct with tTA driven by the neuron specific Synapsin promoter and a 
responder Ptet-bi construct expressing the proteins, improved Cre recombinase (iCre), 
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and Venus fluorescence were cloned into the rAAV backbone as listed (Figure 2.3 a). 
First the cultured primary hippocampal neurons were co-infected with both rAAV-
Syn-tTA and rAAV-Ptetbi-iCre-Venus viruses. Both unpurified viruses, 0.5 µl each, 
were added into each well of a 24-well plate, which had a cultured neuron density of 
about 50,000 cells/well. Ten days after the co-infection, strong Venus fluorescence 
was detected in almost all the neurons in the culture. And the cultured neurons were 
later immunostained with rabbit anti-Cre antibody, which was visualized with Cy3 
coupled secondary antibody. The Venus fluorescence and Cy3 signal were co-
localized in nearly 100% of the infected neurons. The iCre signal was detected mainly 
in nuclei, while Venus was distributed over the whole cell, including soma, dendrites 
and axons (Figure 2.3 b). 
  
Figure 2.3 Co-infection of rAAV-Syn-tTA and rAAV-Ptetbi-iCre-Venus in primary hippocampal 
neuron culture. (a) Scheme of the tTA inducible system in the rAAV plasmid vector. (b) Fluorescence 
confocal microscopy image of co-infected culture neurons. Ten days after virus co-infection, cultured 
neurons were fixed and iCre signal was detected by a polyclonal primary antibody and Cy3 coupled 
secondary antibody, while the Venus fluorescence was directly imaged. Scale bar: 50 µm. 
 
2.2.1.2 Tetracycline-controlled transactivator (tTA) inducted iCre and Venus 
            expression in the mouse brain 
 
For in vivo application, both activator virus rAAV-Syn-tTA and responder virus 
rAAV-Ptetbi-iCre-Venus were co-injected into cortex (Figure 2.4 a) and 
hippocampus (Figure 2.4 b) of wild-type mouse. Two weeks after virus infection, the  
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Figure 2.4 The tTA inducible gene activation system in mouse cortex and hippocampus by rAAV 
delivery. (a, b) Confocal images of brain sections from a wild-type mouse co-injected with rAAV-Syn-
tTA and rAAV-Ptetbi-iCre-Venus in cortex and hippocampus. Venus was directly imaged and Cre was 
detected with a rabbit polyclonal antibody together with a Cy3 coupled secondary antibody. Nearly 
100% of the Venus positive green cells were Cre positive, in cortex as well as in hippocampus  (a) 
Images of infected cortical region with different magnifications. Scale bar: 50 µm (b) Overview image 
of infected hippocampus and detailed images as boxed. Scale bar: upper 200 µm; lower 10 µm (c) 
Cortical and hippocampal unilateral injection (left hemisphere), cortical projections (boxed region) and 
hippocampal contra lateral hemisphere projections were detected. Scale bar: 200 µm. 
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injected cortical region and the entire hippocampus were infected expressing strong 
Venus fluorescence. Immunostaining with rabbit anti-Cre antibody together with Cy3 
coupled secondary antibody revealed that almost 100% of the infected neurons 
showed both Venus and Cy3 signals. This demonstrates that the rAAV gene delivery 
method combined with tTA inducible gene activation system can be applied 
successfully in vivo simultaneous delivery of of two heterologous proteins. However, 
there are few cells that are detected either only with green or with red fluorescence. 
Although the virus co-infection obtained very high expression level of both proteins, 
this finding pointed out the unequal expression of the bi-directional Ptet-bi promoter.  
 
Surprisingly, by unilateral rAAV infection in vivo, we found labeled neuron 
projections not only in the injected hemisphere, but also in the contra lateral 
hemisphere in hippocampus (Figure 2.4 c). Since the mouse was injected only 
unilaterally, we could predict that the labeled projections in the contra lateral 
hemisphere can only originate from the injected hemisphere. Cortical projection could 
be also distinctly revealed at the injection hemisphere (Figure 2.4 c). 
 
2.2.1.3 The tTA induced functional iCre in Cre-reporter Rosa26R mice 
 
To testify the enzymatic activity of the expressed iCre in vivo via rAAV delivery, we 
co-injected rAAV-Syn-tTA and rAAV-Ptetbi-iCre-Venus into cortex and 
hippocampus of adult Cre-reporter Rosa26R mice (Soriano, 1999). Two weeks later, 
expression of the Cre-dependent lacZ reporter gene indicated successful delivery of 
functional iCre in the injected cortical region and dorsal hippocampus (Figure 2.5).  
                                     
Figure 2.5 LacZ staining of a sagittal brain section from a Cre-reporter Rosa26R mouse co-
injected with rAAV-Syn-tTA and rAAV-Ptetminibi-iCre-Venus. Positive lacZ staining indicated 
the functional iCre in vivo. The infected cortical region and dorsal hippocampal showed positive blue 
staining. Scale bar: 500 µm. 
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2.2.1.4 Reverse tTA (rtTA) induced iCre and tdTomato expression in vivo 
 
To demonstrate the functionality of the reverse tTA (rtTA) in vivo via rAAV delivery 
approach, which is a complementary genetic module uniquely suited for strict and 
rapid gene activation by addition of Doxycycline (Dox) in cultured cells (Gossen and 
Bujard, 1992) and in vivo (Kistner et al., 1996), we used rAAV-Syn-rtTA and rAAV-
Ptetbi-iCre-tdTomato for further in vivo test of the Dox regulated tdTomato 
expression. Viruses were co-injected unilaterally into 8 adult Cre-reporter Rosa26R 
mice. And 6 were treated with 800 mg/l of Dox via drinking water directly after 
injection (two for cortex injection, two for hippocampus injection, and two for both 
cortex and hippocampus injection). Two were left untreated. Two weeks after virus 
infection and Dox induction, robust native red tdTomato fluorescence was detected all 
over at the injection site (Figure 2.6). In contrast, the Dox untreated mice showed 
only very few fluorescent positive cells (data not shown), which was expected and 
could be explained by the leakiness of the Ptet-bi bi-directional promoters (Zhu et al., 
2007). The robust native tdTomato fluorescence indicates the successful Dox 
induction in rtTA inducible gene activation system combined with rAAV gene 
delivery approach. 
 
Due to the strong and stable tdTomato fluorescence, neuronal projections from the 
injection sites to the contra lateral hemisphere and other brain regions, which were 
shown previously by Venus fluorescence, were again clearly visible (Figure 2.6). In 
the brain of only cortically injected mice, the projections from infected neurons are 
observed symmetrically in the injection site and contra lateral cortical region, both 
sides of corpus callosum, thalamus, hypothalamus and striatum (Figure 2.6a). In the 
brain of only hippocampally injected mice, we found again symmetrically projected 
termini of infected neurons in injected hippocampus and contra lateral hippocampus, 
both sides of corpus callosum, thalamus, hypothalamus, striatum, and perifornical 
nucleus. Unilateral cortical projections were also observed in the injected hemisphere 
(Figure 2.6b). Except hippocampus and striatum, the signal of projections from 
infected neurons at the contral lateral side are very weak, and can only be visualized 
with high magnification imaging. We speculate that the number of contra lateral 
projections is lower or much lower than the ones in the injected hemisphere, but the 
existence of these projections proves that the extendibility of the functional activity 
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from a single neuron to the complete neural network. This observation reveals the 
potential possibility how does the individual neuron act in synchronizing neuronal 
activity of both hemispheres of the brain. 
 
 
 
Figure 2.6 Neuronal projections of rAAV-Syn-rtTA and rAAV-Ptetminibi-iCre-tdTomato co-
infected cells by unilateral injection. Two weeks after injection, mice were analyzed and images were 
taken directly by confocal microscopy. Boxed regions are shown in magnification on the right panel. 
(a) Cortical unilateral rAAV co-injection. Neuronal projections were found in contralateral cortex, in 
both sides of thalamus, hypothalamus, striatum, and corpus callosum of the brain.   (b) Hippocampus 
unilateral rAAV co-injection. Projections were found in contra lateral hippocampus, both sides of 
thalamus, hypothalamus, striatum, corpus callosum and perifornical nucleus. (c) Unilateral co-injection 
of both cortex and hippocampus. Projections were found in all regions mentioned above. C, cortex; 
CC, corpus callosum; T, Thalamus; H, hypothalamus; Hip, hippocampus; S, striatum; P, perifornical 
nucleus. Scale bar: 500 µm. 
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(to be continued) 
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Figure 2.7 Co-expression of tdTomato and iCre in injected mouse brain. Two weeks after 
injection, brain sections were stained with a rabbit anti-Cre primary antibody and a FITC coupled 
secondary antibody. Infected neurons were strongly visualized by the native fluorescence of tdTomato, 
while iCre signal was illustrated in the nuclei in green. (a) Overview of infected brain regions, 
including cortex and hippocampus. tdTomato fluorescence was co-localized with FITC signal from 
iCre. Scale bar: 500 µm. (b) Z-project image of a confocal stack of an infected cortical region.  Scale 
bar: 50 µm. (c, d) Images from infected hippocampal CA1 (c) and dentate gyrus (d) regions. Higher 
magnification images from the boxed regions are shown below. Scale bar: 50 µm. 
 
To further demonstrate the bi-directionality of the Ptet-bi promoter in the rtTA 
inducible system, the existence of second delivered gene iCre was revealed by 
immunohistochemistry with a polyclonal rabbit anti-Cre primary antibody and a FITC 
coupled secondary antibody. The Cre positive green cells were detected nearly 100% 
co-localized with tdTomato positive cells (Figure 2.7). Due to the leakiness of the 
Ptet-bi promoters, few single positive cells were also observed (Figure 2.7b). The 
enzymatic activity of iCre was proven by lacZ staining on brain sections showing 
positive blue signals in the injected regions (Figure 2.8), demonstrating the 
functionality of the delivered Cre recombinase. Therefore, in the presence of Dox, the 
full activation of both delivered genes indicates the ability of complete dual-gene 
expression via Dox induction and the bi-directionality of the Ptet-bi responder virus. 
Hence, the combination of Dox dependent rtTA inducible system and rAAV gene in 
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vivo delivery approach could offer great chance for inducible fast gene expression at 
specific brain regions. 
 
      
 
Figure 2.8 LacZ staining of rAAV-Syn-rtTA and rAAV-Ptetminibi-iCre-tdTomato co-infected 
mouse brain sections. Blue staining indicates the enzymatic activity of rAAV delivered iCre at the 
different injection sites in vivo, including only cortical and only hippocampal injections and the 
injection at the both sites. Scale bar: 500 µm. 
 
2.2.2 Efficient and quantitative expression of multiple heterologous proteins in 
         mouse brain via 2A peptide approach 
 
A method allowing for efficient and quantitative co-expression of multiple 
heterologous proteins in neurons in vivo would be highly valuable for many 
applications in neuroscience. As described above, the tTA/rtTA inducible gene 
activation system can be applied together with the rAAV gene delivery approach to 
achieve high expression of multiple genes at the desired brain regions in vivo. 
However, as we described above, in the bi-directional promoters, the expression 
levels of the two Ptet-bi controlled genes are unequal and not quantitative. Therefore, 
self-cleaving peptide bridges, so-called 2A or 2A-like peptide sequences from 
Picornaviridae virus family or insect virus Thosea asigna virus, are considered as an 
alternative and more promising approach for multiple gene expression. 
 
In this set of experiments, we analyzed the efficiency of co-expression of various 
proteins in neurons in vitro and in vivo using a 2A peptide bridge from Thosea asigna 
virus when applied in rAAV delivered genes. We demonstrate that this system has 
clear advantages because it achieves efficient and reliable functional co-expression of 
multiple proteins in neurons at the desired specific brain regions in vivo. And can be 
combined with other inducible genetic mouse models to enable targeted manipulation 
of faithfully labeled neuronal subgroups. Furthermore, the 2A peptide approach can 
Cortex Hippocampus Cortex+Hippocampus 
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be combined with tTA/rtTA inducible gene activation system to not only visualize the 
existence of tTA/rtTA, but also induce the responder gene expression both in vitro 
and in vivo. 
 
2.2.2.1 Plasmid construction of rAAV iCre2A fusion  
 
To introduce the 2A peptide into the rAAV system, 54 base-pair DNA sequence of 
the 2A peptide from Thosea asigna virus was assembled from oligonucleotides 
(Figure 2.9 a). Four plasmids were constructed using either the Kusabira Orange 
(KO, Karasawa et al., 2004) were linked in frame with the DNA sequence of iCre via 
the 2A peptide sequence (Figure 2.9 b). 
 
                     
Figure 2.9 Plasmid constructs of iCre2A fusion in rAAV vector. (a) Amino acid residues of 2A 
peptide from Thosea asigna virus. The cleavage site is indicated with the arrow. Amino acid residues 
in red were added to keep the C-terminal environment constant between different constructs. Bottom: 
Diagram of rAAV vector constructs. (b) Diagram of rAAV vector constructs of iCre2A fusions with 
different fluorescent proteins (GFP, Venus or KO) and two different promoters (CMV or Synapsin 
promoter). Lengths of sequences between ITRs are noted.  
 
2.2.2.2 Quantification of cleavage efficiency of 2A peptide in HEK293 cells 
 
To test the cleavage efficiency of 2A peptide, first pAAV-CMV-iCre2A-EGFP was 
transfected into HEK293 cells (Figure 2.10a).  Three days after transfection, bright 
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EGFP fluorescence was observed in the culture with high tranfection efficiency 
(Figure 2.10b). Western blot analysis was performed with the transfected HEK293 
cell lysates for both EGFP and iCre expression to verify the 2A-mediated cleavage. 
Both full-length protein iCre2A-EGFP and cleaved products, iCre2A and EGFP, were 
detected demonstrating the functional 2A peptide cleavage in HEK293 cells. The 
molecular weight (MW) of the released iCre2A was slightly bigger than that of “wild-
type” iCre (39 kDa, co-transfection of pAAV-CMV-tTA and pAAV-Ptetbi-iCre-
Venus) due to the short, remaining 2A tail of 17 aminoacid residues (40.8 kDa). 
About two-thirds of the full-length protein was cleaved according to the intensity of 
the bands (Figure 2.10c).  
 
Figure 2.10 Constructs of 2A fusion were cleaved in HEK293 cells resulting in functional and 
reliable co-expression of heterologous proteins. (a) Diagram of transfected rAAV vecotor constructs. 
(b)Overlay of fluorescent image and phase image of HEK293 cells transfected with pAAV-CMV-
iCre2A-EGFP.  HEK293 cells were fixed 3 days after transfection and imaged directly by fluorescent 
microscopy. Scale bar: 100 µm. (c) 2A-mediated cleavage in HEK293 cells. Western blots of protein 
extracts from transfected HEK293 cells. The 40.8 kDa iCre2A fusion protein and the 27.3 kDa EGFP 
were detected, and to lesser extent, the 68.1 kDa precursor full-length protein. I: Cells transfected with 
rAAV-CMV-iCre2A-GFP. II+III: Cells co-transfected with rAAV-CMV-tTA and rAAV-Ptetbi-iCre-
GFP. Control: Non-transfected cells. 
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2.2.2.3 Efficient 2A peptide cleavage and co-expression in primary neurons 
 
For virus production, both pAAV-Syn-iCre2A-GFP and pAAV-Syn-iCre2A-Venus 
plasmid constructs were used to generate rAAVs. To examine 2A peptide cleavage 
and functional co-expression of proteins in neurons, we infected rat primary 
hippocampal neurons separately with both rAAVs (each 0.5 µl). Ten days after 
infection, strong green fluorescence was detected nearly in all cultured neurons and 
Venus showed brighter signal than EGFP (Figure 2.11). To demonstrate the co-
expression of EGFP or Venus with iCre, a polyclonal antibody raised against Cre was 
used for the immunohistochemistry and EGFP or Venus fluorescence was directly 
imaged. The 2A-mediated cleavage was supported with the finding that the iCre 
signal was detected exclusively in the nucleus and Venus mainly in the cytosol. Even 
without enhancement, Venus expression was high enough to visualize fine cellular 
processes (Figure 2.11). 
 
  
Figure 2.11 Co-expression of EGFP or Venus with iCre in rat primary hippocampal neuron 
cultures. Confocal images of primary hippocampal neurons infected with rAAV-Syn-iCre2A-EGFP 
(a) and rAAV-Syn-iCre2A-Venus (b). Neurons co-express cleaved and freely diffusible Venus (green) 
and nuclear restricted iCre (red, visualized with Cy3-coupled antibody), indicating that the 2A fusion 
construct was cleaved successfully in situ. Scale bars: 10 µm. 
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To quantitatively determine the efficiency of 2A peptide cleavage, neurons were 
harvested from the rAAV-infected primary hippocampal neuron culture. We found in 
Western blots of neuron lysates high levels of released iCre and Venus together with 
low levels of the full-length protein, indicating efficient 2A-mediated cleavage 
(Figure 2.12b). When compared to cleavage in HEK293 cells (Figure 2.10c), the 
balance between newly synthesized full-length iCre2A-Venus and the released 
iCre2A and Venus appeared much more in favor of cleaved products in neurons, 
indicating that the 2A strategy may be particularly suitable for co-expression in non-
dividing cells such as neurons or in the brain. 
 
Figure 2.12 Western blot analysis of 2A-mediated cleavage in rAAV infected primary 
hippocampal neurons. (a) Diagram of rAAV vector constructs. (b) 2A-mediated cleavage in primary 
hippocampal neuron cultures. Western blots of protein extracts from rAAV-infected hippocampal 
neurons. The 40.8 kDa iCre2A fusion protein and the 27.3 kDa Venus were detected, and to a very 
small extent, the 68.1 kDa precursor full-length protein. I: neurons infected with rAAV-Syn-iCre2A-
Venus. II+III: neurons co-infected with the activator virus rAAV-Syn-tTA and rAAV-Ptetbi-iCre-
Venus. Control: Non-infected neurons. (c) Western blot analysis and quantification of hippocampal 
primary neuron culture infected with rAAV-Syn-iCre2A-Venus. Cell lysate (10 µg) was loaded 
together with none infected neuron lysate, 2ng and 10ng of purified GFP protein. Quantification was 
done by ImageJ, and in comparison to purified GFP, the amount of fluorescent signal from the infected 
neuron culture is equivalent to 5.99 ng (0.11 x 10-4 pmol/cell) of purified GFP protein.  
 
 
 
Results 
 33 
To directly compare the 2A approach with the tTA induced co-expression of  iCre and 
Venus, we used a bi-directional Ptet-bi promoter construct as described before 
(Figure 2.3a, 2.12a). When expressed from this bi-directional promoter, iCre levels 
were much lower than those obtained from the iCre2A-Venus fusion construct when 
normalized to the levels of Venus (Figure 2.12b). The immunosignal of Venus from 
10 µg hippocampal neuron lysate can be quantified and equivalent to 5.99 ng (0.11 x 
10-4 pmol/cell) of GFP protein, as estimated by comparison with purified GFP 
(Figure 2.12c). Assuming that iCre and Venus are released in a one-to-one ratio from 
the iCre2A-Venus fusion construct, the amount of expressed iCre2A is in the same 
range (0.11 x 10-4 pmol/cell) for the iCre2A-Venus expressing cells. This amount of 
expressed iCre was about 6-fold higher with the 2A strategy than with the bi-
directional promoter, demonstrating that expression levels at the left and the right site 
of the bi-directional promoter Ptet-bi are very different. In summary, the 2A peptide 
strategy is superior for quantitative co-expression in heterologous cells and in 
particular in neurons. 
 
2.2.2.4 Enzymatic activity of released iCre2A fusion in CV1/lacZ indicator cells 
 
Due to the 17 amino acid residues from 2A peptide in iCre2A fusion, the enzymatic 
activity of released iCre was comfirmed in CV1/lacZ indicator cells (Shimshek et al., 
2002). In this assay, β-Gal is expressed when iCre enzymatic activity removes the 
floxed stop codon in CV1 cells. The iCre2A-Venus cassette was cloned into the pHD 
vector (Kellendonk et al., 1996). The plasmid pHD-iCre2A-Venus or pHD-iCre was 
cotransfected together with an expression plasmid coding for alkaline phosphatase 
(AP) p-HD-AP into CV1 cells. Three days after transfection, both X-Gal staining and 
fast red staining were performed with the fixed cells to visualize iCre and AP 
expression. The number of AP-positive cells was used for normalization of 
transfection efficiency. Compared with pHD-iCre transfected cells, pHD-iCre2A-
Venus transfected cells showed similar ratio, indicating the enzymatic activity of the 
released iCre2A fusion was completely intact by assaying Cre-mediated activation of 
lacZ expression in the Cre reporter cell line CV1 (Figure 2.13). 
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Figure 2.13 The released iCre after 2A cleavage is functional in cell culture. CV1/lacZ indicator 
cells were co-transfected with pHD-AP together with either pHD-iCre (positive control) or pHD-
iCre2A-Venus. The ratio of blue (iCre recombination positive) to red (alkaline phosphatase positive) 
cell numbers represents efficiency of functional iCre. Values for pHD-iCre2A-Venus infected cells 
were normalized to the positive control and not significantly different (n = 10, P > 0.1). Scale bar: 100 
µm. 
 
2.2.2.5 Functional co-expression in intact brain and in vivo imaging 
 
To examine 2A peptide-mediated cleavage in the intact brain in vivo, we injected 
rAAV-Syn-iCre2A-Venus into cortex and hippocampus of adult Cre-reporter  
Rosa26R mice (Soriano, 1999). Two weeks later, expression of the Cre-dependent 
lacZ reporter gene indicated successful delivery of functional iCre2A (Fig. 2.14a). At 
the injection sites, cytosolic Venus fluorescence and nuclear iCre staining were co-
localized in the very same neurons, confirming the efficient proteolytic processing of 
iCre2A and Venus in vivo (Fig. 2.14b, c). In Western blots from infected brain areas, 
we detected exclusively the released iCre2A and Venus, but not the full-length 
iCre2A-Venus fusion protein (Fig. 2.14d).  
Next, we examined whether in the living animal, the expression level of fluorescence 
would be sufficiently high to enable high resolution imaging of neurons and their 
processes in the intact brain. Indeed, three weeks after infection with rAAV-Syn-
iCre2A-Venus, fluorescence was strong enough to allow for in vivo imaging of 
cortical neurons in anesthetized mice by two-photon microscopy. The labeled neurons 
and their processes, including spines, were readily visible in the superficial cortical 
layers (Fig. 2.14e).   
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Figure 2.14 Functional and reliable co-expression using 2A peptide bridges in vivo and its 
application in life imaging. (a) LacZ staining of a brain section from a Rosa26R mouse injected with 
rAAV-Syn-iCre2A-Venus, indicating the released iCre2A protein was functional in vivo. Only infected 
brain regions showed positive blue signal. Scale bars: 500 µm (b) Confocal image of a brain section 
from a wild-type mouse injected with rAAV-Syn-iCre2A-Venus. Scale bars: 500 µm. (c) Higher 
magnification of the CA1 region. Co-expression of Venus (green) and iCre (red, visualized with Cy3-
coupled antibody) was seen in virtually all infected neurons. Scale bars: 10 µm. (d) Western blots of 
extracts from infected brain regions demonstrate near complete 2A peptide cleavage in vivo. Tissues 
were dissected from brains of non-injected or rAAV-Syn-iCre2A-Venus injected wild-type mice. The 
40.8 kDa iCre2A (left) and the 27.3 kDa Venus (right) were clearly detected, the 68.1 kDa full-length 
protein was hardly visible. Hip: Hippocampus; Cx: Cortex; + = infected with rAAVs. (e) In vivo two-
photon images of rAAV-Syn-iCre2A-Venus infected neurons in somatosensory cortex of a wild-type 
mouse. Cell bodies of neurons in cortex as well as their fine processes were imaged at a depth of 150-
200 µm. Spines are indicated by arrowhead and zoom-in image is shown. Scale bars: 10 µm. 
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Therefore, we conclude that the 2A peptide strategy has a powerful potential for 
combining genetic manipulations with the expression of FPs in subgroups of neurons 
at the specific brain regions, which is absolutely necessary for functional studies using 
optical high resolution analysis in vivo, and in particular for long-term investigations. 
2.2.2.6 Applications of 2A-mediated Cre deletion in genetic mouse models 
For more comprehensive applications of 2A-mediated Cre deletion, we used two 
Cre/LoxP based mouse models, Cre-inducible diphtheria toxin receptor mouse line 
(iDTR) and N-methyl-d-aspartate (NMDA) receptor 1 (GluN1) conditional knockout 
mouse line (NR12lox/2lox, Niewoehner et al., 2007), for generating brain site-specific 
conditional gene knockout (Figure 2.15). These two applications would further 
clarify the widespread use of 2A-mediated Cre deletion combined with rAAV site-
specific delivery in the geneticly manipulated mouse models.  
2.2.2.6.1 Functional iCre expression in Cre-inducible diphtheria toxin receptor 
               (DTR) mice (iDTR) 
To obtain site-specific cell deletion in the mouse brain, we injected rAAV-Syn-
iCre2A-KO into dorsal hippocampus of adult Cre-inducible diphtheria toxin receptor 
(DTR) mice (iDTR), in which a gene encoding DTR is under the control of Rosa26 
promoter in the Rosa26 locus. The DTR expression is dependent on the Cre-mediated 
removal of a transcriptional STOP cassette (Figure 2.15a, Buch et al., 2005). Due to 
the toxicity effects, after the expression of Cre recombinase, the application of 
diphtheria toxin (DT) in the mouse results in efficient cell ablation at the iCre 
expressing sites.  
 
Two weeks after virus infection in hippocampus, DT was applied for 3 times with two 
days interval. And two weeks after DT application, mice were sacrificed for brain 
analysis. Immunostaining with NeuN antibody showed complete ablation of dorsal 
hippocampus (Figure 2.15b). However, red fluorescence of KO could not be detected 
within any healthy neurons,  the KO positive cell debris was observed mainly in the 
infected dorsal hippocampus (Figure 2.15b) indicating the ablated KO positive cells. 
This demonstrated the efficient removal of the STOP cassette by iCre2A fusion and 
DT induced cell death via DTR. This experiment further proves that upon 2A peptide-
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mediated cleavage, the functionality of iCre2A fusion is as serviceable as the “wild-
type” Cre. The application of rAAV-Syn-iCre2A-KO in iDTR mice offers many 
potential options for site-specific cell ablation in the CNS in studying and 
manipulating different brain circuits. 
                               
 
Figure 2.15 Functional applications of Cre expression in genetically manipulated mouse models. 
(a) Scheme of targeted Rosa26 locus of the iDTR mouse line. (b) NeuN staining of a brain section from 
a Cre-inducible DTR mouse 4 weeks after injection (2 weeks after DT application) of rAAV-Syn-
iCre2A-KO into hippocampus. Targeted dorsal hippocampus appears completely ablated. (c) The KO 
red fluorescence only can be detected in cell debris at the injection site, not in any healthy cells 
illustrated with higher magnification in boxed region. Scale bar: 200 µm. (d) Left: Scheme of targeted 
GluN1 gene. Right: Western blots of extracts from infected brain regions. In comparison with 
uninfected ventral hippocampus from the same brain and sample from an uninfected animal, the 
amount of GluN1 subunit showed dramatic reduction demonstrating the successful GluN1 (130 kDa) 
removal in dorsal hippocampus. Hip: Hippocampus; + = virus injected animal. 
 
2.2.2.6.2 Removal of GluN1 in NR12lox/2lox mice upon 2A-meidated Cre expression 
 
For the participation in all NMDA receptor subtypes, the GluN1 subunit is the 
essential component of the NMDA receptor in forming functional receptor channels. 
The GluN1 knockout mice die 8-15 h after birth, indicating its necessity in mouse 
postnatal development (Tsien et al., 1996). By using Cre/LoxP system, the 
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conditional GluN1 knockout mice were generated (Tsien et al., 1996; Niewoehner et 
al., 2007). Instead of traditional method by breeding NR12lox/2lox with other Cre mouse 
lines to obtain site-specific GluN1 deletion in the mouse brain, we applied 2A-
mediated Cre expression via virus in vivo delivery method, and the rAAV-Syn-
iCre2A-Venus was injected into the dorsal hippocampus of a adult NR12lox/2lox mouse. 
Three weeks after virus delivery, the infected hippocampal region was demonstrated 
with Venus fluorescence (data not shown), and the amount of GluN1 subunit showed 
dramatic reduction in dorsal hippocampus in comparison with its none infected 
ventral hippocampal region and the one from none injected NR12lox/2lox mouse (Figure 
2.15c). This evidence confirms the successful delivery of Cre recombinase and the 
efficient GluN1 removal only at the injection site without affecting other brain 
regions, in this case the ventral hippocampus. Hence, in combination with genetic 
mouse models, the 2A-mediated Cre expression has big advantages in generating site-
specific conditional gene knockout animals in different brain regions for further 
behavioral and functional studies.  
 
2.2.3 Functional co-expression of tTA/rtTA with FPs via 2A-mediated cleavage  
 
2.2.3.1 Doxycycline regulated gene delivery by Co-expression of tTA/rtTA with 
            FPs in hippocampal primary neurons 
 
 
Figure 2.16 Application of 2A strategy to tTA/rtTA with other FPs. (a) Diagram of rAAV 
constructs of tTA/rtTA2A fusion with different FPs. Lengths of sequences between ITRs are noted. (b) 
Western blots of protein extracts from rAAV-Syn-tTA/rtTA2A-KO infected primary hippocampal 
neurons. The 30.5 kDa tTA/rtTA2A fusion protein was detected and 55.4 kDa full-length protein was 
not visible. Control: non-infected neurons. 
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Figure 2.17 Infection of rAAVs in primary hippocampal neurons with tTA/rtTA2A fusion 
constructs and Dox administration. (a, b) Ten days after co-infection with rAAV-syn-tTA2A-KO 
and rAAV-Ptetbi-iCre-Venus in cultured neurons, without Dox treatment (a), neurons showed co-
expression of both red and green fluorescence, while with Dox treatment (10 ng/ml) (b), the responder 
Venus fluorescence was turned off. (c, d) Primary hippocampal neurons co-infected with rAAV-syn-
rtTA2A-KO and rAAV-Ptetbi-iCre-Venus showed co-expression of both KO and Venus with Dox 
treatment (10 ng/ml) (c), but no responder activation without Dox induction (d). Scale bar: 20 µm. 
 
To expand our approach and to demonstrate that the auto-proteolytic activity of the 
2A peptide was in dependent of the fused protein domains, we extended the 2A 
strategy to other activators used for conditional gene expressionl, and other FPs. We 
generated constructs contains between N-terminal tTA/rtTA and C-terminal 
Venus/KO linked by the 2A peptide (Figure 2.16a).  
 
When rAAV-Syn-tTA/rtTA2A-KO expressed in primary hippocampal neurons, 
tTA/rtTA2A was released, which detected by Western blot analysis (Figure 2.16b), 
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suggesting that the cleavage within the 2A peptide was independent of the flanking 
polypeptide sequence. To provide proof of principle that tTA/rtTA2A and FPs were 
co-expressed and regulated by Dox, we co-infected cultured neurons with rAAV-Syn-
tTA/rtTA2A-KO and the tTA/rtTA responder virus rAAV-Ptetbi-iCre-Venus (Figure 
2.3a, 2.12a). Without Dox administration, in rAAV-Syn-tTA2A-KO and responder 
rAAV co-infected neurons, 10 days after infection, the co-expression of both KO and 
responder Venus fluorescence could be clearly detected (Figure 2.17a), while in the 
presence of Dox in the culture medium (10 ng/ml), the responder fluorescence Venus 
was turned off and was not visible in the culture (Figure 2.17b). For the Dox 
regulated rtTA induction, with 10 ng/ml Dox concentration, the responder Venus 
fluorescence was induced and was co-localized with KO (Figure 2.17c). Without Dox 
in the medium, only KO was observed (Figure 2.17d), indicating the off stage of the 
responder genes. This further confirmed the co-expression of multiple genes by 2A-
mediated cleavage in the cultured neurons, and the responder genes of tTA/rtTA can 
be regulated simultaneously upon Dox application. 
 
 2.2.3.2 Co-infection of rAAV-tTA/rtTA-2A-fusion and responder rAAVs in  
            wild-type mouse brain 
 
After verifying the feasibility of FP coupled tTA/rtTA induction in cultured neurons, 
which can be regulated by Dox, we co-injected rAAV-Syn-tTA/rtTA2A-KO together 
with the responder rAAV-Ptetbi-iCre-Venus into the cortex and hippocampus of wild-
type C57Bl/6 mice, following without (tTA) and with (rtTA) Dox treatments. We 
observed full activation of the tTA/rtTA responder genes in infected neurons, as 
assessed by Venus fluorescence. The FPs Venus and KO co-localized in most neurons 
at the injection sites, suggesting a high rate of neurons co-infected with both viruses 
(Figure 2.18, 2.19). Even when we consider the constraints of co-infection and 
promoter leakiness of the responder virus (Zhu et al., 2007), our data provide strong 
evidence that 2A peptide bridges can be employed universally for different activators 
and FPs for in vivo applications and that 2A cleavage is independent of the the 
flanking polypeptide sequences. Thus, we conclude that the simultaneous 
visualization of tTA/rtTA with 2A peptide lined FPs and their responder genes 
provides strong proof of high expression level of both activators and responders via 
rAAV in vivo gene delivery approach, and the synchronization of both activator and 
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responder genes can be clearly revealed. The application of this feasible combination 
of multiple systems provides the available possibilities to resolve the issue for the 
brain region specific targeting.  Furthermore, together with the mouse transgenic 
model, it has the potential power for manipulating different brain circuits and brain 
functions.   
   
Figure 2.18.  In vivo tTA expression and its responder activation via 2A peptide cleavage. (a) 
Diagram of the rAAV constructs for the dual virus activator-responder approach. (b) Confocal images 
of a brain section from a mouse co-injected with rAAV-Syn-itTA2A-KO and its responder virus 
rAAV-Ptetbi-iCre-Venus. Neurons expressing tTA were labeled with red fluorescent KO. The 
responder Venus expression driven by tTA was lightly detected. Scale bars: 500 µm. (c, d) At higher 
magnification co-expression of KO and Venus was observed in many of infected cortical (c) and 
hippocampal (d) neurons. Scale bars: 50 µm. 
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Figure 2.19.  In vivo rtTA expression and its responder activation via 2A peptide cleavage. (a) 
Confocal images of a hippocampus section from a mouse co-injected with rAAV-Syn-rtTA2A-KO and 
the responder virus rAAV-Ptetbi-iCre-Venus. Dox treatment was administered directly after injection 
via drinking water. Neurons expressing rtTA were labeled with red fluorescent KO. Venus expression 
driven by rtTA was easily detected. (b, c) With high-magnification images, the co-expression of KO 
and Venus was revealed in nearly all the infected hippocampal (b) and cortical neurons (c). Scale bars: 
50 µm. 
 
2.2.3.3 Application of rAAV-tTA2A-KO in G3 responder mouse line 
 
To verify the silencing issue in tTA responder mouse lines suggested previously (Zhu 
et al., 2007), we injected rAAV-Syn-tTA2A-KO into the cortex and the hippocampus 
of G3 trangenic mice expressing the conditional tTA reporters, lacZ and hGFP 
(Krestel et al., 2001). Two weeks after injection, we observed robust KO expression 
in many infected cortical and hippocampal neurons, as well as in dentate gyrus 
granule cells (Figure 2.20 left). However, little hGFP fluorescence could be detected 
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only in very few cells at the injection sites (data not shown), and the responder gene 
activation upon tTA was very poor (Figure 2.20 right). Although the tTA expression 
reaches a very high level, which now can be illustrated by KO fluorescence, the 
responder genes seem to be still silenced. This finding is consistent with the previous 
suggestion that despite the presence of high levels of virus delivered tTA, the 
responder genes are not able to be postnatally activated, indicating the incapable 
response of the silenced Ptetbi bi-directional promoter. 
 
                 
Figure 2.20 Confocal image of a brain section from a rAAV-Syn-tTA2A-KO injected G3 
responder mouse. Although the expression of tTA could be illustrated by KO fluorescence, there was 
almost no GFP signal could be detected upon tTA activation in the infected brain regions. Scale bars: 
500 µm. 
 
Overall, we conclude that the 2A peptide bridge is a very versatile tool for co-
expression of multiple heterologous proteins in neurons in vitro and in vivo, which 
will greatly facilitate molecular and functional analysis in cellular and system 
neuroscience. 
 
2.2.4 The Cre Complementation system 
 
2.2.4.1 Generation of split-Cre proteins 
 
As applied in previous experiments, Cre/LoxP recombination is the most reqquently 
used method for conditional gene regulation in mice. Although the desired site-
specific expression of Cre recombinase can be now achieved by rAAV delivery 
approach as described above, the cell-type-specific Cre expression in vivo remains an 
issue in many experimental approaches. The currently used promoters for Cre 
expression are often active in a wide range of cell types, and therefore are not suitable 
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for cell-type-specific Cre expression in which the Cre recombinase will be only active 
in subsets of cells. To overcome this limitation, the inactive “split-Cre” fragments 
were designed. The Cre activity is only expressed when two types of Cre fragments, 
which are driven by two different promoters, co-express in same cells. 
   
Figure 2.21 Principle of Cre complementation system and design of split-Cre proteins. (a) N-Cre 
and C-Cre expression are placed under the control of two different promoters (promoter 1 and 2, 
respectively). Only if both promoters are active, functional complementation takes place and LoxP  
flanked sequences are recombined, thereby activating reporter genes. (b) N-Cre and C-Cre-proteins 
were constructed by fusing amino acids 19-59 (N-Cre) or amino acids 60-343 (C-Cre) from Cre 
recombinase DNA sequence to the constitutively active coiled-coil interaction domain of the yeast 
transcription factor GCN4 (GCN4cc). Immunotags (Flag, Myc), a linker sequence as well as a nuclear 
localization sequence (NLS) were also added. 
 
The design and primary cloning of the Cre complementation system (split-Cre) were 
done by the Department of Neurogenetics at the Max Planck Institute of Experimental 
Medicine in Goettingen. To establish this system, the coding sequence of Cre 
recombinase was split into two fragments coding for amino acids (aa) 19-59 and 60-
343 representing the N- and C-terminal parts of Cre, respectively. These fragments 
have been shown to allow functional complementation (Jullien et al., 2003; Jullien et 
al., 2007). To further increase the complemented Cre activity by forcing split-Cre 
interaction, both Cre fragments were fused to the constitutively dimerizing coiled-coil 
leucine zipper domain of the yeast trascriptional activator GCN4 (Hope and Struhl, 
1987). In addition, immunotags, a semi-flexible linker (Jullien et al., 2003) and a 
nuclear localization sequence were added to both protein fragments. The resulting 
split-Cre fusion proteins were named N-Cre and C-Cre, respectively (Figure 2.21). 
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2.2.4.2 Plasmid constructs of split-Cre proteins 
 
The N-terminal and C-terminal Cre sequences were separately cloned into a 
recombinant AAV (rAAV) vector pAAV6P-SEWB (Shevtsova et al., 2005). The 
split-Cre protein expression was driven by cholecystokinin (CCK) 3.0 kb, glutamate 
decarboxylase 67 (GAD67) 3.0 kb, glial fibrillary acidic protein (GFAP) 2.2 kb and 
proteolipidprotein (PLP) 4.0 kb promoter, respectively (Figure 2.22). All 8 plasmids 
were used to generate rAAVs.  
 
             
Figure 2.22 Constructs of split-Cre proteins in rAAV vector. N-Cre and C-Cre sequences were 
placed under the control of GFAP-, PLP-, CCK-, GAD67-promoter, respectively, with indicated 
lengths between ITRs. 
 
2.2.4.3 Cre complementation in vivo via Co-expression of CCK-N-Cre and CCK- 
            C-Cre, PLP-N-Cre and PLP-C-Cre 
 
First, to test the virus mediated Cre delivery, rAAV-CCK-N-Cre and rAAV-CCK-C-
Cre, rAAV-PLP-N-Cre and rAAV-PLP-C-Cre were separately co-injected into cortex 
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and hippocampus of two adult wild-type mice. Three weeks later, the mice were 
analyzed by immunostaining. Rabbit anti-Cre antibody was used for 
Diaminobenzidine-tetrahydrochloride (DAB)  staining to visualize the Cre expression. 
Positive cells were found in both cortex and hippocampus at the injected region 
(Figure 2.23). Although the Cre antibody is only against the C-Cre protein, this could 
still show the successful virus mediated C-Cre transduction in the injection areas.  
               
Figure 2.23 Anti-Cre immunostaining of co-injected Cre complementation viruses three weeks 
post injection. Brain sections showed positive Cre signal restricted to the nuclei in the injected areas. 
(a) Hippocampal section from rAAV-CCK-N-Cre and rAAV-CCK-C-Cre co-injected wild-type mouse. 
Most positive cells are located in the region of the dentate gyrus (boxed region). (b) Cortical section of 
rAAV-PLP-N-Cre and rAAV-PLP-C-Cre co-injected wild-type mouse. Cre signals are found both in 
the cortex (left) and hippocampus (right). Scale bar: 500 µm. 
 
2.2.4.4 Co-expression of PLP-N-Cre and GFAP-C-Cre or CCK-N-Cre and  
            GAD67-C-Cre in P0 injected Rosa26R mouse 
 
Since the Cre antibody that we used above to detect the Cre expression is only aginst 
the C-Cre proteins, although Cre immunostaining was positive after virus delivery, 
the enzymatic activity of complete Cre recombinase still remained unclear. Therefore, 
we co-injected rAAV-PLP-N-Cre and rAAV-GFAP-C-Cre or rAAV-CCK-N-Cre or 
rAAV-GFAP-C-Cre into the cortex, the striatum/subventricular zone (SVZ) and the 
hippocampus of Rosa26R mice at the age P0. Four weeks after injection, we detected 
positive blue cells revealed by lacZ staining at the injected regions indicating the 
success of Cre mediated removal (Figure 2.29, 2.30). Therefore, the mixture of 
viruses expressing N-Cre and C-Cre proteins driven by two different promoters is 
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able to serve as functional Cre recombinase when both promoters are active in same 
cells. The positive blue cells could potentially defined as subpopulations of glia cells 
(Figure 2.29) or local interneurons (Figure 2.30), which have both promoter gene 
expressions, respectively.       
                   
 
Figure 2.24 Brain sections of P0 injected Rosa26R mice with rAAV-PLP-N-Cre and rAAV-
GFAP-C-Cre at the age P28. Viruses were co-injected into hippocampus, striatum and cortex. 
Positive blue cells were detected in all these injection sites. (a) Positive cells in hippocampus (left), in 
dentate gyrus (right). (b) LacZ labeling in striatum (left) and cortex (right). Scale bar: 200 µm. 
 
                
Figure 2.25 Brain sections of P0 injected Rosa26R mice with rAAV-CCK-N-Cre and rAAV-
GAD67-C-Cre at the age P28. LacZ staining showed positive blue cells in cortex (a) and dentate 
gyrus of hippocampus (b), indicating full activity of Cre recombinase in the brain. Scale bar: 200 µm. 
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2.2.4.5 Co-expression of PLP-N-Cre and GFAP-C-Cre or CCK-N-Cre and  
            GAD67-C-Cre in adultly injected Rosa26R mouse 
 
The positive lacZ staining demonstrated the full enzymatic activity of complemented 
Cre recombinase, but the signal could not illustrate the exact cell type. The next 
question we asked is the promoter specificity. We co-injected rAAV-PLP-N-Cre and 
rAAV-GFAP-C-Cre or rAAV-CCK-N-Cre and rAAV-GAD67-C-Cre into the cortex 
and the hippocampus of 10-week old adult Rosa26R reporter mice, respectively. Two 
weeks after infection, brain sections from PLP-N-Cre and GFAP-C-Cre expressed 
animal were stained with rat-anti GFAP and rabbit-anti Cre primary antibodies 
visualizing with FITC and Cy3 coupled secondary antibodies, respectively. We 
obtained nearly 100% co-localization of both antibodies at the injection sites. The 
FITC fluorescence was mainly detected in the peripheral of the glial cells while Cre 
signals are only localized in the nuclei (Figure 2.26). This finding clearly indicates 
the promoter specificity, and the injected rAAV-GFAP-C-Cre is very precisely 
labeling all infected GFAP positive glia cells at the local delivery region.  
 
 
Figure 2.26 Co-localization of injected Rosa26R brain with GFAP and Cre antibodies. Adult 
Rosa26R reporter mouse was co-injected with rAAV-PLP-N-Cre and rAAV-GFAP-C-Cre. Brain 
sections were stained with GFAP (green) and Cre (red) antibodies. (a) Almost all Cre positive cells 
showed also GFAP positive signal in injected hippocampus. Scale bar: 500 µm. (b) Detailed imaged of 
co-localized glia cells. Scale bar: 20 µm. 
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Figure 2.26 Co-localization GAD67 and C-Cre protein. Adult Rosa26R reporter mouse was co-
injected with rAAV-CCK-N-Cre and rAAV-GAD67-C-Cre. Brain sections were stained with mouse 
anti-GAD67 (green) and rabbit anti-Cre (red) antibodies. (a) Overview of co-localized GAD67 and Cre 
signals. Most Cre positive cells are co-localized with Cre positive cells in injected cortical regions. (b, 
c) Detailed imaged of co-localized local interneurons. Scale bar: 10 µm. 
 
Using the same strategy, we co-injected rAAV-CCK-N-Cre and rAAV-GAD67-C-
Cre for investigating the local interneuron promoter specificity. Three weeks after 
virus infection, brain sections were stained with mouse-anti GAD67 and rabbit-anti 
Cre primary antibodies together with FITC and Cy3 coupled secondary antibodies, 
respectively. Although the GAD67 antibody staining is having a very strong 
background, double positive cells are still detectable in the injected regions (Figure 
2.27). 
 
Surprisingly, to further analyze the Cre enzymatic activity in the adult injections, we 
only observed very few LacZ positive blue cells in the injected regions (data not 
shown) for both glia cell and interneuron types. This can be explained by a weak 
expression of the complemented Cre recombinase in individual cells. The LoxP 
cassette in the Rosa26 locus was not able to be modified by such a low Cre 
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concentration after only two to three weeks expression period. In our P0 injected 
animals, the Cre activity was clearly demonstrated by the lacZ staining, but not in the 
injection of adult animals. At the age P0, two different promoters could be presented 
in a subset of glia progenitors that are active for both promoters. It might be that after 
development, the progenitor cells differentiate to only single promoter positive glia 
cells. Thus, if the injection was done at P0, the Cre-mediated LoxP cassette removal 
can be still active at the very early stage, and these double promoter positive gila 
progenitors can be revealed by the positive blue signals even in the adult age. But if 
the virus infection is done in adults, there might be hardly any possibility for 
observing double promoter positive cells in the injected brain regions. However, these 
two speculations do not conflict with the Cre complementation method per se, since 
the Cre complementation relies on the good expression of N-Cre and C-Cre in the 
same cell.  
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3. Discussion 
 
3.1 Gene transfer technology 
 
Cell-type specific manipulation of gene expression is a powerful tool for the analysis of 
gene function and for the generation of animal models. The most common approach to 
achieve this goal is the use of cell-type-specific promoters driving the reporter gene 
expression. However, in transgenic approaches, the activity of short promoter regions is 
in many cases strongly influenced by chromosomal sequences next to the integration site 
of the transgene. This position effect variegation (PEV) has a strong impact on the 
expression level and the activity of the promoter fragment (Palmiter et al., 1991).  
 
There was the expectation that the modification via homologous recombination of 
bacterial artificial chromosome (BAC) covering a large sequence of construct (100 000 – 
300 000 kb in size), should be able to mask the transgene from the chromosomal 
environment. In this case, one would expect that all transgenic animals carrying the very 
same BAC show the same reproducible and stable expression pattern. In the recent study, 
a mitral/tufted cell specific mouse line was generated using BAC transgenic technology. 
The EGFP expression was driven by the Gjα9 promoter, which was within the BAC 
sequence. Although EGFP is not a functional protein, it could help for visualizing cells. 
Most of our BAC transgenic mouse lines had very specific mitral/tufted cell expression, 
and the expression level was high enough for in vivo imaging.  
 
Among all the founders, the tissue specificity was very similar. Most founders had 
expression only in the olfactory bulb, not in other brain regions. All founders, however, 
showed differences in the expression level and the cell specificity of Venus fluorescence. 
It remains still unclear whether partial, instable or multiple integrations of the BAC itself 
were responsible for the observed differences in the expression level and the expression 
pattern of Venus or whether the BACs in general also suffer from position variegation 
effects.  
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3.2 The rAAV gene delivery approach  
 
Regarding the limitations of transgenic technology, such as the long time of generating 
transgenics, the rAAV has emerged as an efficient gene delivery system for the nervous 
system. By stereotactic injection, the rAAVs could target cells in the mouse brain at the 
desired positions. After infection, we observed expression of the transduced gene for up 
to eight months. But more importantly, we could show that the rAAV approach is not 
only very fast, but could be applied also for functional studies of neuronal circuits in the 
brain. And another advantage is that due to the application for gene therapy, the 
production and purification methods are very well standardized, therefore, the helper 
dependent rAAVs are relatively reliable to produce and purify. 
 
The low capacity for transduced genes is the main disadvantage of the rAAV gene 
delivery approach. As AAV, rAAV has a packaging capacity of about 4.7 kb DNA. We 
actually observed in our studies that the optimal packaging length is around 3 - 4 kb of 
DNA between both ITRs. For this length, the rAAV with high infectious titers can be 
easily produced; for bigger constructs (more than 4 kb insertion size) the infectious titer 
of the produced viruses is lower. 
 
In each case, it has to be considered that during any cloning or reproduction of DNA 
procedures of rAAV constructs, the ITRs can get damaged (inverted repeats are very 
unstable when propagated in normal E. coli. strains.). Since the ITRs are obligatory for 
virus packaging, E coli. strains which are recombination defective should be used to 
prevent the loss of ITR sequences. We found that none of either the Sure cell (Stratagen, 
La Jolla, California, USA) nor the DH10B (Invitrogen, Karlsruhe, Germany) strains were 
safe for keeping both ITRs in the vector. Therefore, after every cloning step, the rAAV 
vectors have to be checked again for the presence of both ITRs in the viral sequence by 
restriction digests. 
 
3.3 The Tet-inducible tTA/rtTA system and its responders 
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This study demonstrates that both genetic components of the Dox regulated gene 
expression system can be delivered by the rAAV-mediated gene transfer to specific brain 
regions. Co-infection of both tTA/rtTA activator and responder viruses in hippocampal 
neuron cultures and in the mouse brain showed very robust expression patterns. However, 
as already observed by Zhu et al., 2007, in our study the endogenous tTA-responder 
transgenes could not be activated in the brain by simple injection of rAAV-Syn-tTA2A-
KO into different brain regions. We observed no tTA-resonder expression in any of these 
regions with strong tTA2A-KO expression, as indicated by the expression of KO and 
absence of tTA responsive hGFP. This confirmed our previous finding that upon strong 
tTA expression by rAAV delivery, due to unknown epigenetic silencing mechanisms, the 
responder expression cannot be activated when the tTA responder is inserted into the 
genome of the host. If the tTA-responder is present in an episomal state, as is the case of 
rAAV transduced tTA responder virus, tTA2A-KO can activate the episomal Ptet 
controlled genes.  
 
In principle, the combination of rAAV gene delivery approach and the tTA/rtTA-
inducible system provides two big advantages for the site-specific gene expression. First, 
the expression of rAAV delivered gene(s) can be regulated with Dox. Second, the coding 
capacity of the rAAV delivered gene cassette is increased by twofold, because the tissue 
specific promoter and tTA/rtTA can be delivered with one virus, and the gene(s) of 
interest in a second one. Due to the high co-infection rate, the tTA/rtTA system can be 
applied with high efficiencies. 
 
3.4 The 2A peptide-mediated cleavage and multiple gene co-expression 
 
3.4.1 Comparison of 2A-mediated multiple gene expression with other methods 
 
Our results clearly demonstrate that the self-processing 2A peptide can be used for 
simultaneous expression of at least two proteins in the same neurons. This goal cannot be 
achieved by the use of the IRES element (Douin et al., 2004), the tTA dependent bi-
directional promoter (Baron et al., 1995) or two sequential promoters (Callen et al., 
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2004). In the case of the bi-cistronic mRNAs, the IRES-mediated translation of the 
second gene is severalfold lower than the translation initiation of the first ORF (Douin et 
al., 2004). And for the bi-directional promoter Ptet-bi, the strengths of the left and right 
promoters are not expected to be equal, and the translation efficiencies and mRNA 
stabilities of the left and right gene products can be very different. As we showed in our 
study, the unequal expression of both genes leads to an unpredictable, unbalanced 
expression of the left and right Ptet-bi controlled genes. And in the case of tandem 
promoters in a viral construct, multiple promoters can cause promoter occlusion by 
transcriptional interference (Callen et al., 2004). 
 
Considering the difficulties to achieve reliable co-expression of heterologous proteins 
using current approaches, such as IRES elements, bi-directional or dual promoters, co-
transfection of several plasmids, or co-infection with multiple viruses, it is surprising that 
the use of the 2A peptide has not received more attention. One particular advantage of the 
2A system is the use of only one promoter, which can be cell-type-specific. A second one 
is its small size, and therefore, the potential to design constructs with several 2A elements 
for the expression of multiple proteins. 
 
3.4.2 Quantitative analysis 
 
In our study, we investigated if the 2A peptide approach can be used in neurons in vivo 
for reliable and quantitative co-expression. The co-expression, including a visible 
reporter at sufficient levels (e.g., for live imaging), is particularly important for gene 
transfer experiments, or when using conditional genetic systems. We show that genetic 
switches, such as iCre and tTA/rtTA, are reliably co-expressed with different fluorescent 
reporters and that the 2A “fusion proteins” display full biological activity.  
 
After the gene transfer, the exact quantification of the expression of the delivered gene or 
the transgene by measuring the intensity of reporter fluorescence within and across 
experiments crucially depends on a fixed transgene/reporter expression ratio. Our data 
suggest that the self-processing at the 2A peptide bridge in postmitotic neurons appears to 
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be the method of choice to achieve this in a variety of in vitro and in vivo systems using 
minimally sized genetic elements. And the 2A peptide bridge represents an efficient, 
quantitative and very versatile tool for co-expression of multiple heterologous proteins in 
neurons in vitro and in vivo, which will greatly facilitate molecular and functional 
analysis in cellular and systems neuroscience. 
 
In addition, the usage of the 2A peptide sequence increases the coding capacity for gene 
delivery by rAAV approach. In this study, the 2A peptide has been successfully used to 
co-express the marker fluorescent proteins (FPs) with functional proteins, such as iCre 
and tTA/rtTA. This co-expression offers an opportunity for visualizing the cells that 
express the functionality of active tTA or Cre in vivo, while in tTA and Cre FP fusions, 
the tTA or the Cre enzymatic activity is drastically reduced (personal communication). 
Since it is assumed that the cleavage yields a 1:1 ratio, the expression level of the Cre and 
tTA can be also jugged by the expression level of the FPs. 
 
3.4.3 Delivery of more than two genes by 2A-mediated cleavage 
 
In the presented study, only one 2A peptide sequence was used to co-express two 
heterologous proteins at the same time. As reported before, more than two genes can also 
be expressed by using more 2A peptide sequences, such as gene1-2A-gene2-2A-gene3. 
To date, the most complicated 2A-based construct is the assembly of the four 
transmembrane proteins of the CD3 complex in to a CD3δ2A-CD3γ2A-CD3ε2A-CD3ζ 
(Szymczak et al., 2004) poly protein of around 700 amino acids by using different 2A 
peptide sequences from foot-and mouth disease virus (F2A, 
VKQTLNFDLLKLAGDVESNPGP), equine rhinitisA virus (E2A, 
QCTNYALLKLAGDVESNPGP) and Thosea asigna virus (T2A, 
EGRGSLLTCGDVEENPGP). One important issue that had to be discussed for applying 
the 2A peptide in this study was whether the 2A C-terminal extension on the proteins 
would have some negative effects on their native functions. Szymczak et al. 
demonstrated that each cleavage was highly efficient. After the cleavage between glycine 
and proline, the 2A C-terminal extensions did not affect the ability of the CD3δ, γ, ε 
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subunits to assemble and produce a functional CD3 complex in mice. In our study, we 
observed consistent results that neither iCre2A nor tTA2A/rtTA2A showed loss-of-
function or reduction of efficiency. Thus, the 2A-mediated cleavage could be a very 
suitable choice for the expression of multiple proteins. 
 
In our other studies, we showed that the 2A peptide bridge approach can be also 
successfully applied to secreted (Noggin and BMP2) and membrane proteins 
(Channelrhodopsin2, Chr2 and Halorhodopsin, NhHP), and that even two membrane 
proteins together with a FP (ChR2, NpHP and Venus) can be expressed in a single 
protein fusion linked by two 2A peptide sequences (unpublished data). We, therefore, 
conclude that the 2A peptide-mediated cleavage is a very versatile tool for co-expression 
of multiple heterologous proteins in neurons in vivo, which will provide more 
possibilities for the site-specific gene expression.  
 
3.5 The Cre complementation system: a powerful new tool for mouse genetics 
 
The protein complementation assay (PCA) is a method to directly detect protein-protein 
interactions. The original goal of PAC is the identification of compounds that are 
selective for a target within the biochemical pathway that underlies a physiological 
process or pathology of interest, in particular to identify interaction of small molecules 
(Michnick et al., 2007). In our study, we showed that the PAC approach can be also 
applied for the Cre recombinase. With the successful Cre complementation, we 
introduced a new dimension for controlled DNA recombination in the field of the CNS 
research. Combined with rAAV gene delivery system, very distinct cell types can be 
targeted by the intersection of two promoter activities. By splitting the coding sequence 
of the Cre DNA recombinase into two gene fragments, and by the generation of Cre 
fusion proteins with strong protein-protein interaction domains, we were able to establish 
functional complementation of Cre activity in the mouse brain. A comparison of the Cre-
mediated recombination achieved by split-Cre with that of full length Cre, revealed 
similar reporter gene expression patterns in Rosa26R mouse line (Figure 2.24, 2.25 and 
Figure 2.8, 2.14a, respectively). Since the number of mouse lines with floxed genes is 
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drastically increasing, the Cre complementation provides a unique platform, which 
permits a well defined and restricted gene deletion in neuronal subpopulations 
characterized by the overlapping activity of two promoters.  
 
As the N-Cre and C-Cre interaction domain, the GCN4-coiled coil domain has been used. 
It forms very stable homo-dimers (Hope and Struhl, 1987), and enables the functional 
complementation of dihydrofolate reductase in vitro and in E. coli (Pelletier et al., 1998) 
as well as for Tobacco Etch virus protease in vitro (Wehr et al., 2006). However, we 
cannot entirely exclude the possibility that our constructs interfere with cellular 
physiology by binding to endogenous proteins. We did not observe any obvious 
abnormality of the injected mice. Therefore, we assume that expression of N-Cre and C-
Cre using the present promoters does not interfere with mouse physiology. And this 
hypothesis still needs to be substantiated by electrophysiology profiles of N-Cre and C-
Cre expressing neurons as it was achieved in experiments using the 2A peptide.  
 
3.6 Combination of rAAV gene delivery and genetically targeted mouse models 
 
In our study, three genetically targeted mouse lines based on the Cre/LoxP system were 
investigated together with the rAAV in vivo delivery of Cre recombinase into lines 
Rosa26R, iDTR and NR12lox/2lox. The removal of the LoxP cassette can be very well 
activated by the virus delivery of high level of Cre recombinase at the desired brain 
regions. In our study, virus-mediated iCre expression in Rosa26R mice (injected with 
only rAAV-Syn-iCre2A-Venus, or co-injected of rAAV-Syn-tTA together with rAAV-
Ptetbi-iCre-Venus) resulted in strong blue signals in infected hippocampi and cortices. 
Similarly the iCre expression in iDTR mice (injected with rAAV-Syn-iCre2A-KO) 
showed complete ablation of dorsal hippocampi. Both examples indicate a successful 
removal of LoxP-flanked transcriptional stop cassettes in the Rosa locus. However, by 
applying the virus-mediated Cre complementation system in the Rosa26R mouse line, we 
did not detect robust LacZ expression. It is possible that due to the requirement of certain 
Cre expression levels for the accessibility of the Rosa locus, the relatively low expression 
of complemented Cre was not able to induce high reporter expression, which resulted 
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only low expression of LacZ in P0 injected Rosa26R mice, and even almost no LacZ 
signal with the adult-injected Rosa26R mice. 
 
For the conditional knockout models, the combination of 2A-mediated Cre expression via 
rAAV gene delivery is very useful and a flexible tool for site-specific gene deletion. With 
the visualization of Cre recombinase by FPs, the conditional gene knockout also can be 
localized to individual neurons for further electrophysiologic applications. By Western 
blot analysis, the NR12lox/2lox mice injected with rAAV-Syn-iCre2A-Venus showed 
dramatic reduction of the GluN1 subunit in the injected hippocampal region 3 weeks after 
injection. Behavioral and electrophysiologic experiments based on this virus-induced 
conditional GluN1 knockout can further be performed to study channel functions and 
properties in selected brain regions. 
 
3.7 Future perspectives 
 
This study combined a variety of newly developed biological tools, and took the 
individual advantages to further achieve the tissue-specific gene expression and 
manipulation in the mouse brain.  The application of local rAAV gene delivery provides 
a wide range of research perspectives for studying the function of local brain circuits. In 
particular, in combination with genetically modified mouse strains, the local gene 
expression or deletion can be easily accessed at the desired brain regions. Moreover, the 
Dox regulated tTA/rtTA system together with 2A-mediated cleavage can elevate the 
flexibility of the gene regulation. Taken together, many further behavioral and functional 
experiments can be designed with this combination to obtain site-specific and cell-type-
specific gene manipulation in the mouse brain.  
Materials and Methods 
 59 
4. Materials and Methods 
 
4.1 Standard molecular methods 
 
For the applied standard molecular biological methods refer to: Molecular Cloning: a 
Laboratory Manual (3rd Edition; Sambrook J, Russell DW; Cold Spring Harbor 
Laboratory Press, 2001), Current Protocols in Molecular Biology (Ausubel FM, Brent 
R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K; Wiley Interscience, 
1989), Manipulating the Mouse Embryo (Hogan B, Beddington R, Costantini F, Lacy 
E; Cold Spring Harbor Laboratory Press, 1994). 
 
4.2 List of mouse lines 
 
G9GFP (BAC line, generated), C57Bl/6 Charles River (Germany) or RCC/BRL 
(Basel, Switzerland), Rosa26R (Soriano P, 1999), iDTR  (Buch T et al., 2005), 
NR12lox/2lox (Niewoehner et al., 2007), G3 ((Krestel et al., 2001). 
 
4.3 Generation of a BAC transgenic mouse line 
 
4.3.1 Bacterial artificial chromosome (BAC) recombineering by homologous  
         recombination 
 
Bacterial artificial chromosome (BAC) recombineering was done as described 
(Copeland et al., 2001; Liu et al., 2003) by Genesat project at the Rockefeller 
University (http://www.gensat.org/index.html). The modification of Gjα9-EGFP 
BAC was described before (Gong et al., 2002). 
 
4.3.2 Southern blot 
 
Southern blot analysis was applied to confirm the correct BAC modification. NEBlot 
Phototope Kit and Phototope-Star Detection Kit  (New England Biolabs, Catalog 
number N7550S, N7020S, Frankfurt am Main, Germany) were used for this non-
radioactive southern blot method. Biotinylated probes were synthesized and used for 
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hybridization to the target nucleic acid immobilized on a membrane. The target 
nucleic acid was detected by an enzyme catalyzed light-emitting reaction. 
 
Probes were synthesized first by PCR reaction (primer p-GFP5sep and p-VPGFP1), 
an approximately 500 bp long template DNA was generated. About 5 ng to 1 µg 
template DNA were denatured at 99 °C for 5 minutes and incubated at 37 °C for the 
calculated reaction time with 10 µl of 5x labeling mix (contains biotinylated random 
octamers), 5 µl of dNTP mix (contains dNTP and biotin-dATP) and 1 µl of Klenow 
fragment (3’→5’ exo-). Synthesized probes were precipitated and resuspended in 20 
µl of 1x TE buffer for further use. 
 
Sample DNA (5 µg) was separated on a 1.5% agarose gel at 30 V for 12 - 16 hours. 
DNA was visualized by a brief incubation in ethidium bromide. Then it was 
denatured in 1.5 M NaCl/0.5 M NaOH for 30 minutes and neutralized in 1.5 M 
NaCl/1.5 M Trishydroxyaminomethan (Trizma. Sigma, Steinheim, Germany), pH7.4. 
Subsequently, DNA was transferred overnight onto a nitrocellulose membrane 
(Porablot. Macherey-Nagel, Düren, Germany) through a concentration gradient from 
20xSSC to 5xSSC. Membranes were washed in 5xSSC, air-dried and UV-cross linked 
twice. Then the membrane was place in a hybridization bag and prehybridized for 1 
hour at 68 °C in prehybridization solution. Approximately 20 ng/ml of denatured 
probes were hybridized with the membrane 6 hours up to overnight at 68 °C. After 
hybridization, the membrane was removed from the bag and washed twice in 2xSSC, 
0.1% SDS at room temperature for 5 minutes each time and washed twice in 
0.1xSSC, 0.1% SDS at 68 °C for 15 minutes each. The membrane was then placed 
into blocking solution for 5 minutes at room temperature. Using 0.05 ml of diluted 
streptavidin per cm2 of membrane, it was incubated for 5 minutes at room 
temperature. The membrane was again washed twice after streptavidin incubation 
with wash solution I, and incubated 5 minutes with 0.05 ml of diluted phosphatase per 
cm2 of membrane and washed once with blocking solution and twice with wash 
solution II. CDP-Star reagent was used for detection. 
 
4.3.3 Bacterial artificial chromosome (BAC) DNA purification 
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The Bacterial artificial chromosome (BAC) DNA (50 µg) was digested with NotI in 
reaction buffer together with 2.5mM spermidine (Sigma, Steinheim, Germany). 
Digested BAC DNA was loaded on a sucrose gradient. After 20 hours centrifugation 
at 35 kg, fractions were taken (150 µl each) and from every 4th fraction 10 µl were 
loaded on a 1% agarose gel. Positive fractions were determined after gel 
electrophoresis. Separated linearized BAC DNA was collected from all positive 
fractions and purified with Microcon Centrifugal Filter (Millipore Schwalbach, 
Germany).  
 
4.3.4 Pronuclear injection of purified BAC DNA and mouse tail genotyping 
 
Pronuclear injection was done by Biotechnologielabor (BTL), Die Interfakultäre 
Biomedizinische Forschungseinrichtung (IBF), Heidelberg. Purified BAC DNA was 
injected at a concentration of 1 µg/ml into pronuclei of C57Bl/6 mice zygotes. 
Transgene F0 generation was identified by mouse tail genotyping using 3 PCR 
primers (p-Gja9-geno5S: GGTTGGGACGCACATAGATTGCTTC, p-Gja9-geno-
wt3AS: CGGGTAATCCCTTAATGCAGGCAAC, p-EGFP-147-3AS: 
GCAGATGAACTTCAGGGTCAGCTTGC) amplifying a 362bp DNA fragment for 
transgenic mice and a 440bp fragment for wild type mice. Transgenic mouse lines 
were maintained in the IBF. 
 
4.3.5 Immunohistochemistry of mouse brain sections 
 
Mice were anesthetized with Isofluran and either decapitated directly or perfused 
intracardiacly with warm 1xPBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4/2H2O, 1.4 mM KH2PO4) and 4% paraformaldehyde (PFA) in PBS prior to 
decapitation. Brains were removed and fixed in ice-cold 4% PFA for 2 hours, 
embedded in 2.5% Agarose/1xPBS and sliced on a vibratome (VT1000S, Leica, 
Wetzlar, Germany) into 70-100 µm sections.  Fluorescent sections were partially 
analyzed directly under the microscopy after mounting with Aqua Poly/Mount 
(Polysciences, Inc., Warrington, PA, USA) and cover slips. Sections for 3,3-
Diaminobenzidine-tetrahydrochloride (DAB) staining were treated with 0.5% H2O2/ 
1xPBS for 15 minutes at room temperature to reduce endogenous peroxidase activity. 
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Blocking step was done in 4% normal goat serum/ 1% bovine serum albumin (BSA)/ 
0.3% Triton X-100 (Sigma, Steinheim, Germany). Sections were incubated overnight 
at room temperature in primary antibody diluted in 1xPBS/ 1% BSA/ 1% normal goat 
serum/ 0.3 % Triton X-100: anti-GFP 1:10,000 (polyclonal, Abcam, Cambridge, UK); 
anti-Cre 1:3000 (rabbit polyclonal, Covance, California, USA). The second day 
sections were washed twice in 1xPBS/0.3% BSA/ 0.1% Triton X-100 (D2 buffer) 
followed by secondary antibody incubation diluted 1:600 staining (peroxidase-labeled 
anti-mouse, anti-rabbit or anti-goat secondary antibody. Vector Laboratories, 
Burlingame, CA, USA) for 1 hour at room temperature. After two times wash with 
D2 buffer and 1 time with 1xPBS, signals were detected using 0.04% 3,3-
Diaminobenzidine-tetrahydrochloride (DAB, Fluka, Fuchs, Switzerland) in 20mM 
Tris-HCl pH 7.6/ 0.025% H2O2 . Three washes in 1xPBS were used to stop the color 
reaction. Sections were mounted on glass slides with Aqua Poly/Mount and cover 
slips. Immunofluorescent staining was done with the same procedures as DAB 
staining, but without H2O2 treatment at the beginning and with primary antibodies: 
anti-Cre 1:3000 (rabbit polyclonal. Covance, California, USA); anti-NeuN 1:1000 
(mouse monoclonal. Chemicon, California USA), anti-GFAP 1:1000 (rat monoclonal. 
ZYMED, San Francisco, California, USA) and anti-GAD67 (monoclonal. Chemicon, 
California USA), and Cy3 or Cy5 coupled secondary antibody (1:200 dilution, 
Jackson ImmunoResearch, West Grove, PA, USA). Samples were mounted on glass 
slides with Aqua Poly/Mount (Polyscience, Inc., Eppelheim, Germnay) and cover 
slips. 
 
4.3.6 The X-gal staining for vibratome sections 
 
Vibratome sections were incubated in X-gal solution (5mM K4Fe(CN)6, 
5mMK3Fe(CN)6, 2 mM MgCl2, 2 mg/ml X-Gal in Dimethylformamid /1xPBS.  
Sigma, Steinheim, Germany) at room temperature 5 to 60 minutes. Sections were 
washed in 1xPBS and once 10 mM Tris-HCl pH7.5, and mounted on glass slides with 
Aqua Poly/Mount (Polyscience, Inc., Eppelheim, Germnay) and cover slips. 
 
4.3.7 Fluorescent light imaging and confocal imaging 
 
Light and fluorescent images were acquired on a Zeiss Axioplan2 (Carl Zeiss, Jena, 
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Germany) with a camera system AxioCam HRC (Carl Zeiss, Jena, Germany),  2.5x to 
40x dry or 63x oil-immersion objectives, software (Axiovision version 4.6.3), a 
compact light source (Leistungselectronic Jena GmbH, Jena, Germany), 488nm filter 
and 568nm filter. Confocal images were acquired either on a Zeiss LSM5 PASCAL 
coon-focal laser scanning microscope with 63x oil-immersion objective, equipped 
with an Argon laser (457, 476, 488, 514 nm) and a Helium Neon laser (543nm) (Carl 
Zeiss, Jena, Germany) or a Leica TCS SP2 confocal microscope (Leica, Wetzlar, 
Germany) with 10x to 63x glycerin-immersion objectives, equipped with an Argon 
UV laser (352, 364 nm), an Argon laser (457, 476, 488, 514 nm), and two Helium 
Neon lasers (543 and 633 nm, respectively). Image analysis was done with imageJ 
(v10.2), Leica Confocal Software (LCS) or Imaris (Bitplane, Zürich, Switzerland).  
 
4.4 Recombinant adeno-associated virus (rAAV) delivery system 
 
4.4.1 List of plasmids 
pAAV-Syn-tTA Zhu et al., 2007 
pAAV-CMV-tTA Zhu et al., 2007 
pAAV-Ptetbi-iCre-Venus Zhu et al., 2007 
pAAV-Syn-rtTA Hasan MT 
pAAV-Ptetbi-iCre-tdTomato  Hasan MT 
pAAV-CMV-iCre2A-GFP Generated  
pAAV-Syn-iCre2A-GFP Generated 
pAAV-Syn-iCre2A-Venus Generated 
pAAV-Syn-iCre2A-KO Generated 
pAAV-Syn-tTA2A-Venus Generated 
pAAV-Syn-tTA2A-KO Generated 
pAAV-Syn-rtTA2A-Venus Generated 
pAAV-Syn-rtTA2A-KO Generated 
pHD-iCre Shimshek et al., 2002 
pHD-AP Shimshek et al., 2002 
PHD-iCre2A-Venus Generated 
pAAV-CCK-N-Cre  Zhu P 
pAAV-CCK-C-Cre  Zhu P 
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pAAV-GAD67-N-Cre Generated 
pAAV-GAD67-C-Cre Generated 
pAAV-GFAP-N-Cre  Zhu P 
pAAV-GFAP-C-Cre  Zhu P 
pAAV-Plp-N-Cre) Zhu P 
p-AAV-Plp-C-Cre  Zhu P 
 
4.4.2 Construction of rAAV 2A containing plasmids 
 
The Thosea asigna virus 2A peptide coding sequence together with 5’-CTC and 3’-
GCACCGGGATCCACC flanking sequences was synthesized and subcloned between 
BamHI and AgeI sites of plasmid pAAV-6P-SEWB (Shevtsova et al., 2005). The 
iCre gene sequence (Shimshek et al., 2002) was cloned between the Synapsin 
promoter and the 2A peptide sequence to generate pAAV-Syn-iCre2A-EGFP. The 
pAAV-CMV-iCre2A-EGFP was constructed by substitution of the promoter for 
Synapsin by the CMV promoter from pAAV-CMV-tTA (Zhu et al., 2005). The 
Venus sequence was inserted as PCR product by 5’-blunt end 3’-BsrGI ligation into 
pAAV-Syn-iCre2A-EGFP vector in place of EGFP. The tTA and KO (Karasawa, S. 
et al., 2004) sequences were generated by PCR to replace iCre and Venus sequences 
in pAAV-Syn-iCre2A-Venus, respectively. For construction of plasmid pHD-iCre2A-
Venus, the iCre2A-Venus fragment was isolated from plasmid pAAV-Syn-iCre2A-
Venus with EcoRI and BsrGI and subcloned between BglII and XhoI in plasmid 
pHD-iCre (Shimshek et al., 2002) by 5’- and 3’- blunt ligation to replace iCre 
sequence. All plasmids were sequenced after cloning. 
4.4.3 Construction of rAAV Cre-complementation plasmids 
 
For Cre-complementation experiment, the N-terminal and C-terminal sequences were 
separately constructed into recombinant AAV (rAAV) backbone flanked by AAV2 
ITRs by 5’-AgeI and 3’HindIII, and driven by CCK 3.0 kb, GAD67 3.0 kb, GFAP 2.2 
kb and PLP 4.0 kb promoter, respectively, inserted as 5’-BspMI-blunt, XbaI-blunt and 
3’-SalI into p-AAV6P-SEWB (Shevtsova et al., 2005). All plasmids were sequenced 
after cloning. 
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4.4.4 Preparation and purification of rAAVs 
 
A cross-packaging of AAV serotype 1 and serotype 2 were performed by triple-
transfection of rAAV vector plasmids and both p-DP1 and p-DP2 plasmids that 
express the AAV2 rep and cap genes as well as the adenovirus E4, VA, E2a helper 
regions into HEK 293 cells (Zhu et al., 2007; Grimm et al., 2003). Virus was 
harvested by three times freezing and thawing as described before (During et al., 
2003).  Virus purification was performed by Iodixanal gradient as introduced 
(Zolotukhin et al., 1999). Infectious titers of rAAVs from all fluorescent expressing 
constructs were determined by infection of hippocampal primary cultures (5 × 104 cell 
per well in 24-well plates). At 4 days in vitro, neurons were infected with 0.1 µl virus. 
After two weeks, fluorescent cells were counted to calculate the infectious titer 
(1.0×107-108 particles/ml for all rAAVs). The rAAVs were stored at -70°C. 
4.4.5 CV1 cell Transfection and Staining Assays 
 
Experiment design was described as before (Shimshek et al., 2002). HEK293 cells 
were transfected as previously described (Shimshek et al., 2002) with pAAV-CMV-
iCre2A-EGFP. Other plasmids (pHD-iCre2A-Venus and pHD-iCre) were separately 
co-transfected with control plasmid (600 ng/well) pHD-AP into CV1/lacZ indicator 
cells in 24-well plate. The β-gal and alkaline phosphatase activities were detected by 
X-Gal solution and Fast Red staining solution (Roche, Mannheim, Germany). Cre 
activity is indicated by the ratio of blue to red cells. 
4.4.6 Hippocampal primary cultures and rAAV infection  
 
Dissociated hippocampal neurons of E18 rats were plated at a density of 5 × 104 cells 
per well in 24-well plates coated with poly-L-lysine (Sigma, Steinheim, Germany, 
Brewere et al., 1993). Neurons were infected with rAAVs after 4 days in vitro, and 
evaluated by Western blots or immunohistochemistry 10 days post infection. 
4.4.7 Stereotactic injections 
 
All procedures were performed according to the guidelines of the local animal use and 
care committees. Five to six-week old mice (C57Bl/6, Rosa26R, iDTR or NR12lox/2lox) 
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were deeply anesthetized (Ketamine/Xylazine mix or isofluorane), and the head was 
shaved and disinfected. Animals were fixed in a sterotactic frame (Kopf Instruments, 
California, USA), and the skin overlying the skull was cut. Small holes were drilled in 
the skull at coordinates AP –2.1 mm, Lat ± 1.6 mm relative to bregma to target the 
hippocampus. Virus was injected at depths of 350 µm, 1100 µm and 1600 µm, 
delivering ~300 nl at each step via glass pipettes (tip diameter 10-20 µm). The skin 
was sutured, and the wound disinfected. Analgesic (Metacam, Boehringer Ingelheim, 
Germany) was administered before and after surgery. 
 
4.4.8 Mouse P0 injections 
 
The rAAV particles were injected into newborn Rosa26R mice, cryo-anaesthesized on 
ice for 5 minutes. Using a UMP2 micro injection pump (World Precision Instruments, 
Sarasota, FL, USA) with a hamilton 710 syringe, 1 µl virus was injected bilaterally 
into the brain ventricles and hippocampus, 2 mm rostral and 0.7 mm lateral from 
lambda at a depth of 1.8 mm measured from the skin, and 1mm rostral and 1mm 
lateral from lambda at a depth of 1.5 mm measured from the skin, respectively.  The 
animals were recovered on a heating pat after injection and grew up with their mother 
in the home cage. Four to six weeks later, injected animals were sacrificed for 
immunohistochemistry analysis. 
 
4.4.9 Protein extraction and Western blot analysis 
 
For protein analysis, HEK293 cells were harvested 48h after transfection. Primary 
hippocampal cultures were harvested with lysis buffer (50 mM Tris-HCl, pH7.6; 5 
mM MgCl2; 130 mM NaCl; 10 mM KCl; 1% Triton X-100; 5% Glycerin) 10 days 
after virus infection. Brain tissues (cortex and hippocampus) was collected two weeks 
after virus infection and homogenized in ice-cold buffer (25 mM Hepes, pH 7.4) 
containing a protease inhibitor cocktail (CompleteTM; Roche, Mannheim, Germany). 
From rAAV infected neuron cultures, 10 µg of total cell lysate and 20 µl of culture 
medium were separated by SDS-Page gel. Samples were run on SDS-polyacrylamid 
gels (10% separating and 4% stacking gels) and transferred to nitrocellulose 
membranes. Western blots were probed with polyclonal rabbit anti-Cre (1:8000, 
Covance, California, USA), monoclonal mouse anti-GFP (1:10000, Clontech, 
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California, USA), polyclonal rabbit anti-tTA (1:10,000, provided by Prof. Dr. 
Wolfgang Hillen, Institute of Biology, Friedrich-Alexander University, Erlangen, 
Germany), and monoclonal rat anti-Noggin (1:1000, R&D Systems, Wiesbaden, 
Germany) antibodies. Horseradish peroxidase-linked anti-rabbit, anti-mouse or anti-
rat were used as secondary antibodies (1:15000, Vector Laboratories, Peterborough, 
UK). Blots were visualized by enhanced chemiluminescence (ECL kit, Amersham 
Pharmacia Biotech, Freiburg, Germany). Quantification of Western blots was done by 
ImageJ (NIH, Washington D.C., USA).  
4.4.10 In vivo two-photon imaging.  
 
Two-photon imaging was performed three weeks after virus injection into 
somatosensory cortex using a custom-built two-photon microscope (Hasan et al., 
2004). Mice were anesthesized with urethane (1.5 mg/g) and body temperature was 
maintained at 37°C. A custom-built headplate with an imaging window (4 × 3 mm) 
was glued to the top of the skull using cyano-acrylate (Uhu, Bühl/Baden, Germany) 
and attached to a fixed metal bar. The microscope objective was positioned so that the 
optical axis was perpendicular to the surface of the cortex. Two-photon image 
sequences were collected in regions of interest with a MicroMax, 512 × 512 back-
illuminated CCD camera (Roper Scientific, Duluth, GA, USA).  
 
4.4.11 Diphtheria toxin administration 
 
Two weeks after virus injection, diphtheria toxin (DT) (Sigma, Stinheim, Germany)  
was i.p. injected 3 times, each two days, at dose 25 ng/g mouse body weight. Mice 
were analyzed 2 weeks after last DT injection. 
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6. Abbreviations  
 
α   alpha  
α-   anti  
β   beta 
µ   micro  
BAC   bacterial artificial chromosome  
bp   base pair  
BSA   bovine serum albumin  
CCK   cholecystokinin 
Cre   Cre-Recombinase 
CMV   cytomegalovirus 
CNS   central nervous system 
Cx   connexin 
DAB   diaminobenzidine-hydrochloride 
DNA   desoxyribonucleic acid  
DG   dentate gyrus  
EC   entorhinal cortex  
EDTA   ethylenediaminetetraacetic acid  
EPL   external plexiform layer 
FP   fluorescent protein 
g   gram 
GABA   γ-aminobutyric acid 
GAD67   glutamate decarboxylase 67 
GCL   granule cell layer 
GFAP   glial fibrillary acidic protein 
GFP   green fluorescent protein  
Gjα9   gap junction α9 
GL   glomerular layer 
IPL   internal plexiform layer 
IRES   internal ribosomal entry sites 
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ITR   inverted terminal repeat 
kb   kilobase pair  
kDa   Kilodalton 
M   Mol 
MCL   mitral cell layer 
nls   nuclear localization signal 
NMDA   N-methyl-D-aspartate  
OB   olfactory bulb 
ONL   olfactory nerve layer 
OSN   olfactory sensory neurons 
P   postnatal day 
PA   Polyadenylation signal  
PCR   polymerase chain reaction 
PBS   Phosphate based buffer solution  
PFA   Paraformaldehyde  
pH   potential Hydroxyl 
rAAV   Recombinant adeno-associated virus 
rtTA   reverse tetracycline-controlled transactivator 
SDS   Sodium dodecyl sulfate  
SSC   Sodiumchloride-Sodiumcitrate-Solution 
tTA   tetracycline-controlled transactivator 
X-gal   5-Brom-4-Chlor-3-Indolyl-b-D-Galactopyranoside 
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